{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## LangChain Tutorial - Part 3: Retrievers"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Setting UP...\n",
    "\n",
    "Before starting this tutorial, please follow the steps bellow:\n",
    "  \n",
    "1. **Download the PDF Article to be used in this Tutorial**:\n",
    "    - Article: [Pancreatic Cancer: A Review](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363152/).\n",
    "    - Create the folder `./documents` (if necessary).\n",
    "    - Download the article to the `./documents` folder.\n",
    "        - Expected: ./documents/nihms-1828057.pdf\n",
    "\n",
    "2. **Load the `.env` File**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext dotenv\n",
    "%dotenv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# This is the question to be answered\n",
    "question = \"What percentage of patients have pathogenic germline gene variants?\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: langchain_community in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (0.3.2)\n",
      "Requirement already satisfied: pypdf in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (5.0.1)\n",
      "Requirement already satisfied: PyYAML>=5.3 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (6.0.2)\n",
      "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (2.0.35)\n",
      "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (3.10.10)\n",
      "Requirement already satisfied: dataclasses-json<0.7,>=0.5.7 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (0.6.7)\n",
      "Requirement already satisfied: langchain<0.4.0,>=0.3.3 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (0.3.3)\n",
      "Requirement already satisfied: langchain-core<0.4.0,>=0.3.10 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (0.3.10)\n",
      "Requirement already satisfied: langsmith<0.2.0,>=0.1.125 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (0.1.135)\n",
      "Requirement already satisfied: numpy<2.0.0,>=1.26.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (1.26.4)\n",
      "Requirement already satisfied: pydantic-settings<3.0.0,>=2.4.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (2.5.2)\n",
      "Requirement already satisfied: requests<3,>=2 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (2.32.3)\n",
      "Requirement already satisfied: tenacity!=8.4.0,<9.0.0,>=8.1.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain_community) (8.5.0)\n",
      "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (2.4.3)\n",
      "Requirement already satisfied: aiosignal>=1.1.2 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.3.1)\n",
      "Requirement already satisfied: attrs>=17.3.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (24.2.0)\n",
      "Requirement already satisfied: frozenlist>=1.1.1 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.4.1)\n",
      "Requirement already satisfied: multidict<7.0,>=4.5 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (6.1.0)\n",
      "Requirement already satisfied: yarl<2.0,>=1.12.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from aiohttp<4.0.0,>=3.8.3->langchain_community) (1.15.2)\n",
      "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain_community) (3.22.0)\n",
      "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from dataclasses-json<0.7,>=0.5.7->langchain_community) (0.9.0)\n",
      "Requirement already satisfied: langchain-text-splitters<0.4.0,>=0.3.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain<0.4.0,>=0.3.3->langchain_community) (0.3.0)\n",
      "Requirement already satisfied: pydantic<3.0.0,>=2.7.4 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain<0.4.0,>=0.3.3->langchain_community) (2.9.2)\n",
      "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain-core<0.4.0,>=0.3.10->langchain_community) (1.33)\n",
      "Requirement already satisfied: packaging<25,>=23.2 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain-core<0.4.0,>=0.3.10->langchain_community) (24.1)\n",
      "Requirement already satisfied: typing-extensions>=4.7 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langchain-core<0.4.0,>=0.3.10->langchain_community) (4.12.2)\n",
      "Requirement already satisfied: httpx<1,>=0.23.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langsmith<0.2.0,>=0.1.125->langchain_community) (0.27.2)\n",
      "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langsmith<0.2.0,>=0.1.125->langchain_community) (3.10.7)\n",
      "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from langsmith<0.2.0,>=0.1.125->langchain_community) (1.0.0)\n",
      "Requirement already satisfied: python-dotenv>=0.21.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from pydantic-settings<3.0.0,>=2.4.0->langchain_community) (1.0.1)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from requests<3,>=2->langchain_community) (3.4.0)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from requests<3,>=2->langchain_community) (3.10)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from requests<3,>=2->langchain_community) (2.2.3)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from requests<3,>=2->langchain_community) (2024.8.30)\n",
      "Requirement already satisfied: greenlet!=0.4.17 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from SQLAlchemy<3,>=1.4->langchain_community) (3.1.1)\n",
      "Requirement already satisfied: anyio in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain_community) (4.6.2.post1)\n",
      "Requirement already satisfied: httpcore==1.* in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain_community) (1.0.6)\n",
      "Requirement already satisfied: sniffio in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain_community) (1.3.1)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain_community) (0.14.0)\n",
      "Requirement already satisfied: jsonpointer>=1.9 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.4.0,>=0.3.10->langchain_community) (3.0.0)\n",
      "Requirement already satisfied: annotated-types>=0.6.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.3->langchain_community) (0.7.0)\n",
      "Requirement already satisfied: pydantic-core==2.23.4 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.3->langchain_community) (2.23.4)\n",
      "Requirement already satisfied: mypy-extensions>=0.3.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain_community) (1.0.0)\n",
      "Requirement already satisfied: propcache>=0.2.0 in /Users/eduardo.hamerski.br/.pyenv/versions/3.12.5/lib/python3.12/site-packages (from yarl<2.0,>=1.12.0->aiohttp<4.0.0,>=3.8.3->langchain_community) (0.2.0)\n",
      "Note: you may need to restart the kernel to use updated packages.\n"
     ]
    }
   ],
   "source": [
    "# Install the packages langchain_community and pypdf\n",
    "%pip install --upgrade langchain_community pypdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import the class PyPDFLoader from the package langchain_community.document_loaders\n",
    "from langchain_community.document_loaders import PyPDFLoader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create an instance of PyPDFLoader\n",
    "# Inform the PDF file to be loaded\n",
    "loader = PyPDFLoader(\"./documents/nihms-1828057.pdf\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "28\n"
     ]
    }
   ],
   "source": [
    "# Load and split the PDF file in chunks of data\n",
    "# You can pass an optional text splitter instance to the `load_and_split` method\n",
    "# When it is not informed, the method uses a default RecursiveCharacterTextSplitter instance:\n",
    "# - chunk_size...: 4000 (max number of characters per chunk)\n",
    "# - chunk_overlap:  200 (number of characters to overlap between chunks)\n",
    "pages = loader.load_and_split()\n",
    "print(len(pages))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 0}, page_content='Pancreatic Cancer: A Review\\nWungki Park, MD ,\\nDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York\\nDavid M. Rubenstein Center for Pancreatic Cancer Research, New York, New York\\nDepartment of Medicine, Weill Cornell Medical College, New York, New York\\nParker Institute for Cancer Immunotherapy, San Francisco, California\\nAkhil Chawla, MD ,\\nDepartment of Surgery, Northwestern Medicine Regional Medical Group, Northwestern University \\nFeinberg School of Medicine, Chicago, Illinois\\nRobert H. Lurie Comprehensive Cancer Center, Chicago, Illinois\\nEileen M. O’Reilly, MD\\nDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York\\nDavid M. Rubenstein Center for Pancreatic Cancer Research, New York, New York\\nDepartment of Medicine, Weill Cornell Medical College, New York, New York\\nAbstract\\nIMPORTANCE— Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, \\nwith approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC \\nis increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of \\ncancer-related mortality by 2030.\\nOBSERVATIONS— Effective screening is not available for PDAC, and most patients \\npresent with locally advanced (30%–35%) or metastatic (50%–55%) disease at diagnosis. A \\nmultidisciplinary management approach is recommended. Localized pancreas cancer includes \\nresectable, borderline resectable (localized and involving major vascular structures), and locally \\nadvanced (unresectable) disease based on the degree of arterial and venous involvement \\nby tumor, typically of the superior mesenteric vessels. For patients with resectable disease \\nat presentation (10%–15%), surgery followed by adjuvant chemotherapy with FOLFIRINOX \\nCorresponding Author:  Eileen M. O’Reilly, MD, Memorial Sloan Kettering Cancer Center, 300 E 66th St, Office 1021, New York, \\nNY 10065 (oreillye@mskcc.org).\\nAuthor Contributions:  Dr O’Reilly had full access to all of the data in the study and takes responsibility for the integrity of the data \\nand the accuracy of the data analysis.\\nConcept and design:  All authors.\\nAcquisition, analysis, or interpretation of data:  All authors.\\nDrafting of the manuscript:  All authors.\\nCritical revision of the manuscript for important intellectual content:  All authors.\\nObtained funding:  Park, O’Reilly.\\nAdministrative, technical, or material support:  Park, O’Reilly.\\nSupervision:  O’Reilly.\\nOther - involved in writing:  Chawla.\\nHHS Public Access\\nAuthor manuscript\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nPublished in final edited form as:\\nJAMA . 2021 September 07; 326(9): 851–862. doi:10.1001/jama.2021.13027.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 1}, page_content='(fluorouracil, irinotecan, leucovorin, oxaliplatin) represents a standard therapeutic approach with \\nan anticipated median overall survival of 54.4 months, compared with 35 months for single-agent \\ngemcitabine (stratified hazard ratio for death, 0.64 [95% CI, 0.48–0.86]; P = .003). Neoadjuvant \\nsystemic therapy with or without radiation followed by evaluation for surgery is an accepted \\ntreatment approach for resectable and borderline resectable disease. For patients with locally \\nadvanced and unresectable disease due to extensive vascular involvement, systemic therapy \\nfollowed by radiation is an option for definitive locoregional disease control. For patients with \\nadvanced (locally advanced and metastatic) PDAC, multiagent chemotherapy regimens, including \\nFOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil, all have \\na survival benefit of 2 to 6 months compared with a single-agent gemcitabine. For the 5% to \\n7% of patients with a BRCA  pathogenic germline variant and metastatic PDAC, olaparib, a \\npoly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that \\nimproves progression-free survival following initial platinum-based therapy.\\nCONCLUSIONS AND RELEVANCE— Approximately 60 000 new cases of PDAC are \\ndiagnosed per year, and approximately 50% of patients have advanced disease at diagnosis. The \\nincidence of PDAC is increasing. Currently available cytotoxic therapies for advanced disease \\nare modestly effective. For all patients, multidisciplinary management, comprehensive germline \\ntesting, and integrated supportive care are recommended.\\nApproximately 60 430 new diagnoses of pancreatic cancer are anticipated in the US in \\n2021.1 The incidence is rising at a rate of 0.5% to 1.0% per year, and pancreatic cancer \\nis projected to become the second-leading cause of cancer death by 2030 in the US.1,2 \\nPancreatic ductal adenocarcinoma (PDAC) accounts for the majority (90%)of pancreatic \\nneoplasms, and the other subtypes include acinar carcinoma, pancreaticoblastoma, and \\nneuroendocrine tumors. Most patients with pancreatic cancer present with nonspecific \\nsymptoms at an advanced stage with disease that is not amenable to curative surgery.1 \\nNo effective screening exists. The 5-year survival rate approached 10% for the first time in \\n2020, compared with 5.26% in 2000.1 The survival improvements have been modest and \\nattributed primarily to multiagent cytotoxic therapies.3–5 Recently, comprehensive germline \\nand somatic genomic sequencing became standard of care for small subgroups of patients \\nwith targeted treatment opportunities.6,7 Olaparib, a poly (adenosine diphosphate[ADB]-\\nribose) polymerase inhibitor, can prolong cancer control in patients with a BRCA1/2 \\npathogenic germline variant.8,9 This review summarizes current evidence regarding \\npathobiology, diagnosis, and management of PDAC.\\nMethods\\nA PubMed search was performed for English-language articles describing randomized \\nclinical trials, meta-analyses, and systematic reviews of pancreatic cancer published between \\nJanuary 1, 2010, and July 5, 2021. We identified 43 randomized clinical trials, 85 meta-\\nanalyses, and 171 systematic reviews. The authors selected articles for inclusion, prioritizing \\nrecent randomized clinical trials of higher quality based on rigor of study design, adequate \\nsample size, and long-term follow-up. A total of 24 randomized clinical trials, 4 meta-\\nanalyses, 3 systematic reviews, 5 guideline recommendations, and 37 observational and \\ncohort studies, including publications prior to 2010, were included.Park et al. Page 2\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 2}, page_content='Epidemiology and Screening\\nPDAC is the third-leading cause of cancer mortality in the US and the seventh-leading cause \\nworldwide (Box).10The median age at diagnosis in the US is 71 years, and PDAC is slightly \\nmore common in men than in women (5.5 vs 4.0 per 100 000 individuals).11At presentation, \\n50% of patients have metastatic disease, 10% to 15% have localized disease amenable to \\nsurgery, and the remainder (30%–35%) have locally advanced mostly unresectable disease \\ndue to the extent of tumor-vascular involvement.1 Pancreatic intraepithelial neoplasms \\n(PanINs) refer to precancerous lesions, of which a small fraction may progress to high-grade \\ndysplasia and PDAC.12 Low-grade PanINs are common and their potential to transform \\ninto a malignancy is unclear. In a retrospective review of 584 patients who underwent a \\npancreatectomy for non-PDAC (median age, 59 years), 153 patients (26%) were identified \\nwith PanINs; most patients had low-grade PanIN-1 (50%) or PanIN-2 (41%) and 13 (8%) \\nhad PanIN-3. None of the patients with PanIN-3 developed cancer, whereas 1 patient with \\nPanIN-1B developed cancer in 4.4 years.13 Intraductal papillary mucinous neoplasms are \\nmore common precancerous cystic lesions than PanINs and can arise in either the main \\nor branch pancreatic duct. In a cohort study of 605 patients who underwent a surgical \\nprocedure for intraductal papillary mucinous neoplasms, the malignancy rate for final \\npathology in main-duct intraductal papillary mucinous neoplasms was 68%, whereas in \\na different cohort study of 1404 patients with branch-duct intraductal papillary mucinous \\nneoplasms, only 15% evolved to PDAC over 15 years.14–16 Annual imaging surveillance \\nis recommended; however, there is no consensus as to the optimal surveillance method or \\nfrequency of assessment.15,17 For asymptomatic average-risk individuals, the US Preventive \\nServices Task Force recommends against routine screening for PDAC.18\\nModifiable and Inherited Risk Factors\\nAmong lifestyle risk factors, current cigarette smoking has the strongest association \\nwith PDAC. A meta-analysis of 12 case-control studies that included 6507 patients with \\npancreatic cancer and 12 890 control patients reported an odds ratio (OR) of 1.74 (95% CI, \\n1.61–1.87) for the association of current smoking with pancreatic cancer (absolute rates not \\nreported).19,20 There was also a modest association of alcohol use with PDAC, when intake \\nexceeded 30 g per day (approximately 3 drinks per day), according to a meta-analysis of 19 \\nprospective studies reporting outcomes from 4 211 129 individuals (relative risk, 1.22 [95% \\nCI, 1.03–1.45]; absolute rates not reported).21 Chronic pancreatitis was associated with a \\n13-fold increased risk for PDAC in a pooled analysis of 14 prospective cohort studies of \\n862 664 individuals (relative risk, 13.3 [95% CI, 6.1–28.9]).22 Obesity, defined as a body \\nmass index in the fifth quintile (highest 20%), was also associated with an increased risk \\nof PDAC (incidence, 14.1 vs 5.7 per 100 000 person-years; adjusted relative risk, 1.54 \\n[95% CI, 1.04–2.29]) in a Norwegian analysis of 940 060 individuals.23 Diets of processed \\nmeat, high-fructose beverages, and saturated fat were associated with obesity, diabetes, and \\npancreatic cancer.24 The incidence of PDAC in people younger than 30 years is increasing. \\nThe annual incidence of PDAC increased with younger age from 1995 to 2014, from 0.77% \\n(95% CI, 0.57%–0.98%) for those aged 45 to 49 years, to 2.47% (95% CI, 1.77%–3.18%) \\nfor those aged 30 to 34 years, to 4.34% (95% CI, 3.19%–5.50%) for those aged 25 to 29 \\nyears, consistent with an increase in younger patients.24 This observation may be related Park et al. Page 3\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 3}, page_content='to increasing rates of obesity and diabetes, which are potentially modifiable risk factors for \\nPDAC.\\nAbout 3.8% to 9.7% of patients with PDAC have pathogenic germline gene variants \\nthat increase susceptibility to PDAC. These variants occur mostly in DNA damage repair \\ngenes.25–27 The most common variants in PDAC include BRCA2 , BRCA1  (hereditary breast \\nand ovary cancer syndrome), and ATM  (ataxia telangiectasia syndrome). Germline BRCA2 \\nvariants are associated with an increased risk for PDAC (OR, 9.07 [95% CI, 6.33–12.98]) \\nmore commonly than BRCA1  (OR, 2.95 [95% CI, 1.49–5.60]) or ATM  variants (OR, \\n8.96 [95% CI, 6.12–12.98]).28 Uncommon (1% of patients with PDAC) but therapeutically \\nimportant inheritable germline variants also occur in PDAC in mismatch repair deficiency \\ngenes MLH1 , MSH2 , MSH6 , and PMS2  as part of Lynch syndrome.29 In 2019, the National \\nComprehensive Cancer Network guidelines recommended that all patients newly diagnosed \\nwith PDAC undergo germline testing with a gene panel including BRCA1/2, ATM, MLH1, \\nMSH2, MSH6 , and PMS2 .30 Healthy family members are also recommended for genetic \\ncounseling if an individual is determined to be at high risk based on the following criteria: \\na first-degree relative with early-onset PDAC (<50 years), more than 1 first-degree family \\nmember with PDAC, or a known pathogenic germline gene variant associated with PDAC. \\nFor optimal genomic testing, a multigene panel is recommended over traditional hierarchical \\nsingle-gene testing for efficiency and cost.30\\nMolecular Profiling of Pancreatic Cancer\\nThe pathophysiology of PDAC is characterized by complex multistep genetic alterations. In \\nthe precancerous state, PanINs acquire cumulative genetic insults resulting in instigating \\noncogenes that are responsible for the initiation and maintenance of PDAC, including \\nKRAS , CDKN2A , TP53 , and SMAD4 .31 KRAS  variants occur as an early step in PDAC \\ndevelopment (low-grade PanINs) and are identified in 90% to 92% of individuals with \\nPDAC. As PanIN progresses to grade 2 or 3, additional gene variants in CDKN2A , \\nTP53 , and/or SMAD4  are acquired.31 Collectively, these genomic alterations contribute \\nto multifaceted defects in tumor suppressor mechanisms resulting in dysregulated growth \\nsignaling and inflammation, which are key aspects of PDAC. Additionally, about 10% to \\n15% of PDACs acquire variants in the SWI/SNF chromatin remodeling genes related to \\nlarge-scale structural genomic aberrations.32\\nRecent advances in molecular pathology and classification of PDAC have affected clinical \\npractice.32–35 One example is subtyping of PDAC into “basal-like” or “classical” type by \\nRNA transcriptional analyses.34–36 The classical subtype of PDAC is characterized by a \\nhigher level of differentiation, fibrosis, and inflammation, whereas the basal-like subtype is \\nassociated with a poorer clinical outcome and loss of differentiation. The value of selecting \\ntherapies based on PDAC subtypes is under investigation in prospective trials.37,38 Whole-\\ngenome structure analysis has provided insight into genomic instability and the relationship \\nwith DNA maintenance genes ( BRCA1/2  and PALB2 ) and, specifically, genetic signature \\n3. These findings suggest that platinum-based therapy and poly (ADP-ribose) polymerase \\ninhibitors may be effective for patients with pathogenic variants in BRCA1/2  and PALB2 .32 Park et al. Page 4\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 4}, page_content='One prospective trial building on these observations has led to the approval of the targeted \\nagent olaparib in select patients with BRCA1/2  pathogenic germline variants.8,9,33,39,40\\nClinical Significance of Immune Tumor Microenvironment\\nPDAC cells exist in an impenetrable network, also known as the tumor microenvironment \\n(TME ), which comprises immune cells, cytokines, metabolites, fibroblast, and desmoplastic \\nstroma rich in hyaluronan. The immunosuppressive TME helps PDAC cells evade host \\nimmune surveillance. A potent host anticancer T cell memory against PDAC neoantigens \\nhas been identified in 82 select long-term survivors of PDAC who lived more than 3 \\nyears after undergoing surgery.41 However, in most patients, the TME suppresses the \\nimmune system and antagonizes host anticancer immunity and promotes carcinogenesis. \\nThe TME of PDAC is characterized by limited infiltration of CD8+ T cells and an \\nabundance of myeloid derived suppressor cells, tumor-associated macrophages, tumor-\\nassociated neutrophils, and regulatory T cells. Additionally, the extracellular matrix, \\ncharacterized by distinctive desmoplasia stemming from cancer-associated fibroblast, matrix \\nmetalloproteinases, and hyaluronan, may promote the immunosuppressive characteristic of \\nthe TME. These multifaceted compartments are viewed as responsible, in part, for the \\nresistance to most single-agent therapeutic approaches.42–45 Many clinical trials that are \\nunderway are designed to increase the sensitivity of PDAC to the immune system with \\nthe goal of overcoming the immunosuppressive characteristic of the TME (eTable 1 in the \\nSupplement).46,47\\nClinical Manifestations and Presentation of Pancreatic Cancer\\nThe presenting symptoms of PDAC are often vague and nonspecific. Most patients \\npresent with either locally advanced (unresectable) or metastatic disease. In a prospective \\ncohort study of 391 participants 40 years or older who were suspected of having PDAC, \\ninitial symptoms were compared among 119 participants who were ultimately diagnosed \\nwith PDAC, 47 with other cancers, and 225 without PDAC. In this study, no initial \\nsymptoms differentiated participants diagnosed with PDAC from those who ultimately \\ndid not have PDAC, including the 3 most common symptoms: decreased appetite (28% \\nvs 31%), indigestion (27% vs 39%), and change in bowel habit (27% vs 22%).48 Most \\ntumors (approximately 70%) arise at the head of the pancreas and often present with \\nbiliary obstruction leading to dark urine (49%), jaundice (49%), appetite loss (48%), \\nfatigue (approximately 51%), weight loss (approximately 55%), and exocrine pancreatic \\ninsufficiency (25%). In contrast, individuals with body and tail pancreatic cancers present \\nwith more nonspecific symptoms, including abdominal pain, back pain, and cachexia-related \\nsymptoms (appetite loss, weight loss, fatigue). New-onset or worsening of preexisting \\ndiabetes may be a sign of PDAC and warrants evaluation.49 Rarely, acute pancreatitis can be \\na primary manifestation of PDAC and occurs in about 3% of patients with newly diagnosed \\nPDAC. Referral to an experienced multidisciplinary team is recommended.Park et al. Page 5\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 5}, page_content='Diagnosis and Evaluation of Pancreatic Cancer\\nPancreas computed tomography (CT) angiography with chest and pelvis CT can be used \\nin the assessment of vascular anatomy and stage of disease and are recommended at \\ndiagnosis. The degree of contact between the tumor and local blood vessels (ie, the superior \\nmesenteric and portal veins as well as the celiac, hepatic, and superior mesenteric arteries) \\nis categorized as either uninvolved, abutted, or encased. Abutment implies that the tumor \\nhas 180° or less of blood vessel involvement and encasement implies greater than 180° \\nof circumferential tumor-vessel involvement (Figure 1). This information is important to \\ndefine the most optimal initial treatment. Common sites of PDAC metastases are liver \\n(90%), lymph nodes (25%), lung (25%), peritoneum (20%), and bones (10%–15%).3 \\nMagnetic resonance imaging and cholangiopancreatography can help determine whether \\nindeterminate liver lesions are likely to represent metastases and identify cancers that \\nmay be poorly characterized on CT imaging. Positron emission tomography/CT using a \\nfluorodeoxyglucose tracer is a functional imaging tool that evaluates glucose metabolism in \\nthe tumor and can help distinguish benign from malignant lesions in the pancreas; however, \\nit lacks the spatial resolution and can detect glucose uptake from infection, inflammation \\nalso confounding interpretation.50 Positron emission tomography/CT is not considered a \\nroutine staging tool.\\nEndoscopic ultrasonography is used to visualize a pancreas mass directly, secure a definitive \\ncytologic or histologic diagnosis, define the degree of tumor-vascular involvement, evaluate \\nregional lymph nodes, and evaluate the potential for complete resection. Fine-needle \\ncore biopsy (preferred over fine-needle aspiration) of a tumor guided by endoscopic \\nultrasonography is recommended to obtain a histologic diagnosis and to provide material \\nfor molecular testing (Table 1). Visualization of an obstructed biliary tree is performed \\nby endoscopic retrograde cholangiopancreatography, with decompression most often \\nachieved by placing a metallic biliary stent. Serum carbohydrate antigen 19–9 is a well-\\nestablished biomarker for PDAC and is useful for monitoring treatment response. Although \\ncarbohydrate antigen 19–9 is not sufficiently sensitive or specific for routine screening, \\nits value as a screening tool is being revisited.51,52 Other investigational blood-based \\nbiomarkers, including cell-free DNA, exosomes, and circulating tumor cells, may also be \\nuseful for monitoring treatment response and evaluating therapy resistance.53\\nClinical Staging and Multidisciplinary Management of Localized Disease\\nResectability, defined as the ability to completely remove the cancer, is assessed to select \\ntreatment for localized PDAC (Table 1).54 The American Joint Committee on Cancer \\n(AJCC) tumor, node, and metastasis classification is used to assess prognosis.55 For the \\npractical treatment planning, each case is defined as resectable PDAC, borderline resectable \\nPDAC (BRPC), or locally advanced PDAC (LAPC) based on the degree of tumor contact \\nand invasion into the superior mesenteric, hepatic artery, or celiac vasculature (Figure 1). \\nLocalized disease consists of a spectrum of resectability, including resectable (operable), \\nborderline resectable, and locally advanced and inoperable disease. Characterizing localized \\ndisease is best performed by multidisciplinary review, including physicians from surgical \\noncology, radiology, medical oncology, and radiation oncology disciplines. Several Park et al. Page 6\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 6}, page_content='classifications of resectability are used.56 Tumors are typically considered resectable when \\nthere is minimal or no contact with major vessels. However, BRPC may have venous \\ninvolvement and/or partial arterial involvement. There is growing interest in evaluating \\nneoadjuvant systemic therapy with or without radiotherapy for BRPC and resectable PDAC. \\nLocally advanced PDAC is unresectable at presentation due to vessel invasion.\\nThe optimal procedure for resection of the primary tumor depends on tumor location and \\nits relationship to the bile duct and vasculature. Generally, tumors in the pancreas head \\nand uncinate process require a pancreaticoduodenectomy, or “Whipple procedure,” while \\ntumors in the pancreatic neck (without bile duct involvement), body, and tail require a \\ndistal pancreatectomy. Vessel invasion may require vascular resection and reconstruction. \\nPancreaticoduodenectomy is associated with high rates of adverse events, including delayed \\ngastric emptying (10%) and pancreatic leak (13%).57 The best outcomes are attained by \\nsurgeons who perform more than 20 pancreaticoduodenectomy procedures per year and \\nconduct surgery in a high-volume center. Minimally invasive pancreatectomy has been \\ndemonstrated to be safe, with similar complication rates as open pancreatectomy (OR, 0.67 \\n[95% CI, 0.39–1.16]) as well as shorter hospital stay (weighted mean difference, 3.7 days) \\ncompared with open pancreatectomy.58,59 Pancreatectomy should be performed when a \\nmargin-negative resection is feasible. En bloc resection and reconstruction of the portal vein \\nin patients with tumor invasion into this blood vessel is used to obtain a margin-negative \\nresection. This undertaking results in a similar prognosis than in patients whose tumors do \\nnot invade the portal vein and is standard therapy for patients with BRPC.60\\nCurrent multidisciplinary management paradigms include early integration of supportive \\ncare, prehabilitation strategies with physical therapy, occupational therapy (prior to \\nproceeding to the operating room), nutritional management (including pancreas enzyme \\nsupplementation), advance care planning, and increasing use of patient-reported outcome \\nmeasures to enhance quality of life (eTable2 in the Supplement).61\\nAdvances in Adjuvant Therapy for Resected Pancreatic Cancer\\nThe recommended adjuvant chemotherapy after resection of PDAC is either modified \\nFOLFIRINOX (fluorouracil, oxaliplatin, irinotecan, leucovorin) for individuals with high \\nfunctional status or gemcitabine and capecitabine or gemcitabine alone for individuals \\nwith poorer functional status. Recommendations for adjuvant therapy are based on several \\nimportant trials from the past 2 decades.5,62–64 The main chemotherapy agents are DNA-\\ndamaging agents, which directly affect DNA synthesis and repair (oxaliplatin, irinotecan), \\nand antimetabolites, such as gemcitabine and fluorouracil (Table 2). The efficacy of adjuvant \\nchemotherapy in resected PDAC was defined in the CONKO-001 trial, in which 368 \\npatients who underwent surgical resection of PDAC were randomized to receive 6 months \\nof adjuvant gemcitabine or undergo observation (eTable 3 in the Supplement). Superior \\nmedian overall survival was observed in patients treated with gemcitabine compared \\nwith those who underwent observation (22.8 vs 20.2 months; hazardratio [HR], 0.76 \\n[95% CI, 0.61–0.95]), representing a modest prolongation of survival.62 Subsequent trials \\ncompared gemcitabine with single-agent fluorouracil as well as 2- and 3-drug combination \\nregimens.5,63,64 The ESPAC-4 phase 3 trial demonstrated an added survival benefit of Park et al. Page 7\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 7}, page_content='dual-agent therapy over gemcitabine alone. In this trial, 730 patients were randomized \\nto receive 6 months of adjuvant gemcitabine plus capecitabine, an oral antimetabolite, \\nor gemcitabine alone. Combination therapy improved median overall survival compared \\nwith gemcitabine alone (28.0 vs 25.5 months; HR, 0.82 [95% CI, 0.68–0.98]).64 Most \\nrecently, in the 2018 multicenter PRODIGE-24 trial, 493 patients with resected PDAC, along \\nwith a low serum carbohydrate antigen 19–9 (< 180 U/mL) and an excellent performance \\nstatus (Eastern Cooperative Oncology Group score, 0–1), were randomized to receive 6 \\nmonths of adjuvant modified FOLFIRINOX or gemcitabine alone. In this trial, favorable \\nsurvival occurred in both groups relative to prior trials with gemcitabine in the adjuvant \\nsetting and likely reflected inclusion of more highly selected patients: patients treated with \\nmodified FOLFIRINOX had an overall survival of 54.4 months, compared with 35 months \\nin patients treated with gemcitabine (HR, 0.64 [95% CI, 0.48–0.86]).5 Thus, modified \\nFOLFIRINOX is recommended as standard adjuvant therapy in individuals with excellent \\nfunctional status after surgical resection of PDAC. Overall, patients for whom treatment with \\nmodified FOLFIRINOX is not suitable can be considered for gemcitabine/capecitabine or \\ngemcitabine alone.63,64 The role of radiotherapy as an adjuvant therapy for resected PDAC \\nis controversial. Older studies did not support adjuvant radiation for PDAC because no \\noverall survival advantage has been demonstrated.68,69\\nNeoadjuvant and Perioperative Therapy for Resectable and Borderline \\nResectable Pancreatic Cancer\\nNeoadjuvant therapy, or preoperative therapy, can eradicate occult metastatic disease and \\nincrease the number of patients eligible for systemic therapy. The latter is important because \\na significant percentage of patients are unable to receive adjuvant therapy because of \\noperative morbidity. Recent nonrandomized prospective trials demonstrated high completion \\nrates, of 83% to 90%, in patients receiving neoadjuvant FOLFIRINOX.7,70 In a phase 2 \\ntrial, 39 of 43 patients with BRPC received 4 months of FOLFIRINOX.7,70 Similarly, \\nin the Southwest Oncology Group S1505 trial, 46 of 55 patients completed neoadjuvant \\nFOLFIRINOX therapy.7 Another advantage is potential downstaging prior to undergoing \\nsurgery, facilitating a margin-negative resection.70,71 This was demonstrated in a multi-\\ninstitutional trial that reported improved margin-negative resection rates in patients receiving \\nneoadjuvant therapy compared with initial surgery in 58 patients with BRPC (82.4% vs \\n33.3%; P = .01).72\\nThe role of radiotherapy in localized PDAC remains unclear and is being evaluated in \\nongoing investigations.73–76 Neoadjuvant chemoradiotherapy has demonstrated potential \\nbenefit in the phase 3 PREOPANC trial, in which 236 patients were randomized to receive \\nneoadjuvant gemcitabine-based chemoradiation followed by surgery or initial surgery, \\nboth followed by adjuvant gemcitabine. An overall survival benefit was observed in the \\npredefined subgroup of 113 patients with BRPC who were treated with neoadjuvant \\nchemoradiotherapy (17.6 vs 13.2 months; HR, 0.62 [95% CI, 0.40–0.95]).74 The \\nALLIANCE A021501 trial, a randomized phase 2 trial, evaluated perioperative modified \\nFOLFIRINOX with or without neoadjuvant stereotactic body radiotherapy in 126 patients \\nwith BRPC. The addition of stereotactic body radiotherapy to neoadjuvant modified Park et al. Page 8\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 8}, page_content='FOLFIRNOX did not improve median overall survival (31.0 months [95% CI, 22.2 to not \\nreached] for the modified FOLFIRINOX group and 17.1 months [95% CI, 12.8– 24.4] for \\nthe modified FOLFIRINOX plus stereotactic body radiotherapy group). Data for both groups \\nwere compared with historical data and the study did not have sufficient statistical power to \\ncompare the groups directly.77 Current guidelines support neoadjuvant chemotherapy with \\nor without radiotherapy as an option in both BRPC and LAPC.54 Eligibility for surgical \\nresection in BRPC and LAPC requires assessment by a multidisciplinary team.\\nThe benefit of neoadjuvant therapy in resectable PDAC is undergoing evaluation. Potential \\nlimitations of neoadjuvant therapy include the lack of a major tumor response to neoadjuvant \\ntherapy in most patients.7Inadequate tumor response may facilitate tumor progression, \\nobviating the opportunity to completely resect the tumor. However, the importance of this \\nphenomenon remains unclear. Neoadjuvant therapy adds complexity to multidisciplinary \\ntreatment planning. It requires a pretreatment biopsy and endoscopic stent placement in \\npatients with biliary obstruction. In patients with resectable disease, preoperative biliary \\ndrainage was associated with perioperative complications, such as pancreatitis in 7% of \\npatients, cholangitis in 26%, stent occlusion in 15%, and postoperative wound infection \\nin 13%.78 A randomized phase 2 Southwest Oncology Group (SWOG) S1505 trial of \\n102 patients evaluated perioperative modified FOLFIRINOX or gemcitabine and albumin-\\nbound paclitaxel. Results showed no difference in overall survival between the modified \\nFOLFIRINOX and gemcitabine plus albumin-bound paclitaxel, with 2-year overall survival \\nrates of 47% (95% CI, 31%–61%) and 48% (95% CI, 31%–63%).7 Uncertainties related to \\nthe efficacy of neoadjuvant therapy in patients with resectable PDAC may be addressed by \\nan ongoing phase 3 trial (A021806) comparing perioperative modified FOLFIRINOX with \\nadjuvant modified FOLFIRINOX in patients with resectable PDAC.\\nTherapy of LAPC\\nLAPC is an inoperable disease at diagnosis, and approximately 80% of patients are \\nunlikely to have sufficient tumor response from neoadjuvant therapy to become eligible \\nfor surgical resection. To achieve disease control, initial treatment typically consists of \\nchemotherapy regimens, such as modified FOLFIRINOX or albumin-bound paclitaxel and \\ngemcitabine.79 The role of radiation in LAPC is controversial. A pooled analysis of 11 \\ntrials involving 794 patients reported that chemoradiation was associated with improved \\nsurvival, compared with radiotherapy alone (2 trials [168 patients]; HR, 0.69 [95% CI, 0.51–\\n0.94]), but chemoradiation followed by chemotherapy did not improve survival more than \\nchemotherapy (2 trials [134 patients]; HR, 0.79 [95% CI, 0.32–1.95]).80 The SCALOP trial \\nevaluated the use of capecitabine or gemcitabine combined with radiation. The capecitabine \\ngroup had superior median overall survival compared with the gemcitabine group (15.2 vs \\n13.4 months; adjusted HR, 0.39 [95% CI, 0.18–0.81]; P = .012).81 The role of radiation, \\nthe optimum radiation modality, and the dosing schedule for radiation in LAPC all remain \\nunclear. Innovative radiation strategies, including high-dose “ablative” radiotherapy, are \\nunder investigation.Park et al. Page 9\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 9}, page_content='Standard Therapies for Metastatic Pancreatic Cancer\\nMultiagent cytotoxic regimens have improved survival in advanced PDAC.3–5,67 Current \\nstandard first-line regimens for patients with metastatic disease include gemcitabine \\nand albumin-bound paclitaxel or modified FOLFIRINOX (Table 2; eTable 3 in the \\nSupplement).3,4 The Metastatic Pancreatic Cancer Trial (MPACT) trial of 861 patients \\nwith untreated metastatic PDAC reported an overall survival benefit for gemcitabine and \\nalbumin-bound paclitaxel compared with gemcitabine (median survival, 8.5 vs 6.7 months; \\nHR, 0.72 [95% CI, 0.62–0.83]; P < .001).4 The PRODIGE trial of 342 patients with \\nuntreated metastatic PDAC reported that mean survival was better with FOLFIRINOX \\ntreatment compared with gemcitabine (11.1 vs 6.8 months; HR, 0.57 [95% CI, 0.45–0.73]; \\nP < .001).3 For 417 patients with metastatic PDAC and disease progression receiving \\ngemcitabine therapy, the NAPOLI-1 trial demonstrated superiority of overall survival for \\nthe combination of nanoliposomal irinotecan, fluorouracil, and leucovorin, with a median \\n6.1 months, compared with fluorouracil and leucovorin, with a median of 4.2 months (HR, \\n0.67 [95% CI, 0.49–0.92]; P = .012).67These trials were conducted in patients without \\nselection for any specific disease or genetic characteristic. In contrast, the POLO (Pancreas \\nOlaparib Ongoing) trial validated a genetic biomarker, germline BRCA1/2  variation, leading \\nto US Food and Drug Administration approval of olaparib, apoly (ADP-ribose) polymerase \\ninhibitor. Olaparib or placebo was administered as a maintenance treatment in patients \\nwith a germline BRCA1/2  variation and metastatic PDAC following initial platinum-based \\nchemotherapy and was approved based on a progression-free survival benefit compared with \\nplacebo (7.4 vs 3.8 months; HR, 0.53 [95% CI, 0.35–0.82]; P = .004).8 Of note, there was \\nno difference in overall survival between the placebo and olaparib groups in the POLO trial \\n(HR, 0.83 [95% CI, 0.56–1.22]; P = .35).\\nSymptom Management and Supportive Care Approaches in Pancreatic \\nCancer\\nSupportive care by a multidisciplinary team should be integrated with therapeutic \\nmanagement of PDAC to maximize length of life, quality of life, and symptom \\ncontrol. Specifically, attention to nutrition, pain management, management of thromboses, \\npsychosocial needs, and advance care planning are among the most important \\nconsiderations.61 Other challenges of PDAC include bile duct and duodenal obstruction. \\nBiliary obstruction is managed with endobiliary metallic stent placement or surgical biliary-\\nenteric bypass.82 Gastric outlet or duodenal obstruction is managed via endoscopic stent \\nplacement, which has been shown to have noninferior efficacy and greater durability relative \\nto gastrojejunostomy.83\\nNovel Therapies for Pancreatic Cancer\\nA subgroup of 10% to 15% of individuals with PDAC have DNA damage repair gene \\nalterations other than BRCA . Novel combination strategies evaluating targeted agents and \\nimmune therapy combinations are undergoing testing for patients with PDAC associated \\nwith impaired DNA damage repair.9,84 Single-agent PD-1 blockade has US Food and Drug \\nAdministration approval for mismatch repair deficiency in any tumor. Mismatch repair Park et al. Page 10\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 10}, page_content='deficiency occurs in approximately 1% of individuals with PDAC and is defined by either \\ngermline or somatic alterations or loss in mismatch repair deficiency genes, such as MLH1 \\nand MSH2 .29,85 KRAS  missense variants in codon G12C in PDAC occur in 1% to 2% of \\npatients with PDAC, and early-phase assessment of the KRAS  G12Callele-specific inhibitor \\nsotorasib demonstrated 1 instance of partial response (>30% tumor reduction) and stable \\ndisease in a cohort of 12 patients with PDAC who have this variation. The KRAS  wild-type \\nsubset of PDAC (absence of KRAS  variation) is observed in 6% to 8% of all patients \\nwith PDAC and in up to 16% to 18% in patients younger than 50 years at diagnosis.86 \\nIn this setting, alternative oncogenic drivers are present and entrectinib and larotrectinib \\nhave activity in TRK  fusion (<1%) and zenocutuzumab (MCLA-128) has activity in NRG-1 \\nfusion (<1%) PDAC.87,88\\nThere are multiple drugs targeting the epithelial component, signaling pathways, \\nmetabolism, and the TME of PDAC (Figure 2). Single or combination immune \\ncheckpoint blockade inhibitors, such as durvalumab and tremelimumab, are ineffective for \\nPDAC.44,45,89 However, an early efficacy signal of an objective response rate of 67% (8 of \\n12 participants in all cohorts and median overall survival of 20.1 months [95% CI, 10.5 to \\nnot estimable] among 24 dose-limiting toxicity-evaluable participants) has been observed for \\nthe combination of the CD40 agonistic antibody sotigalimab with the checkpoint inhibitor \\nnivolumab and chemotherapy.90 Adenosine is an immunosuppressive metabolite in the \\nTME. Depleting adenosine, using both small molecule–targeting agents (eg, AB680) or with \\nantibody therapy (eg, oleclumab), represent novel metabolism-directed approaches being \\ninvestigated in PDAC.91 eTable 1 in the Supplement summarizes select ongoing trials in \\nPDAC.\\nLimitations\\nThis review has several limitations. First, it is not a systematic review and the quality of \\nincluded literature was not formally evaluated. Second, some relevant studies may have been \\nmissed. Third, it does not cover all aspects of the epidemiology, diagnosis, and management \\nof pancreatic cancer.\\nConclusions\\nApproximately 60 000 new cases of PDAC are diagnosed per year, and about 50% of \\npatients have advanced disease at diagnosis. The incidence of PDAC is increasing. Currently \\navailable cytotoxic therapies for advanced disease are modestly effective. For all patients, \\nmultidisciplinary management, comprehensive germline testing, and integrated supportive \\ncare is recommended.\\nSupplementary Material\\nRefer to Web version on PubMed Central for supplementary material.Park et al. Page 11\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='Funding/Support:\\nCancer Center Support Grant P30 CA008748; David M. Rubenstein Center for Pancreas Cancer Research; Paul \\nCalabresi Career Development Award K12 CA184746; Parker Institute for Immunotherapy Pilot Grant; Elsa U. \\nPardee Foundation Grant.\\nConflict of Interest Disclosures:\\nDr Park reported receiving grant and research support from Astellas, Gossamer Bio, and Merck and providing \\nconsultancy to Ipsen. Dr O’Reilly reported receiving grants and research funding to the institution from Genentech-\\nRoche, Celgene-BMS, BioNTech, Arcus, AstraZeneca, and BioAtla; personal fees for serving on a data and \\nsafety monitoring board from Cytomx Therapeutics, Rafael Therapeutics, personal fees from Sobi Consulting, \\nnon-financial support from Silenseed Consulting, personal fees from Molecular Templates Consulting, personal \\nfees from Boehringer Ingelheim Consulting, personal fees from BioNTech Consulting, personal fees from Ipsen \\nConsulting, personal fees from Polaris Consulting, and personal fees from Merck Consulting during the conduct of \\nthe study; other from Bayer Spouse consulting, other from Celgene/BMS Spouse consulting, other from Genentech-\\nRoche Spouse consulting, and other from Eisai Spouse consulting outside the submitted work. No other disclosures \\nwere reported.\\nRole of the Funder/Sponsor:\\nThe funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation \\nof the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for \\npublication.\\nREFERENCES\\n1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–\\n33. doi:10.3322/caac.21654 [PubMed: 33433946] \\n2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting \\ncancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers \\nin the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155 \\n[PubMed: 24840647] \\n3. Conroy T, Desseigne F, Ychou M, et al. ; Groupe Tumeurs Digestives of Unicancer; PRODIGE \\nIntergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. \\n2011; 364(19):1817–1825. doi:10.1056/NEJMoa1011923 [PubMed: 21561347] \\n4. V on Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel \\nplus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369 \\n[PubMed: 24131140] \\n5. Conroy T, Hammel P, Hebbar M, et al. ; Canadian Cancer Trials Group and the Unicancer-GI–\\nPRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl \\nJ Med. 2018; 379(25):2395–2406. doi:10.1056/NEJMoa1809775 [PubMed: 30575490] \\n6. Pancreatic Adenocarcinoma, Version 1.2020. National Comprehensive Cancer Network; 2019.\\n7. Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable \\npancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–427. \\ndoi:10.1001/jamaoncol.2020.7328 [PubMed: 33475684] \\n8. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA -mutated metastatic \\npancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMoa1903387 [PubMed: \\n31157963] \\n9. O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase ii trial of gemcitabine and \\ncisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/\\nPALB2  mutation. J Clin Oncol. 2020; 38(13):1378–1388. doi:10.1200/JCO.19.02931 [PubMed: \\n31976786] \\n10. Wong MCS, Jiang JY , Liang M, Fang Y , Yeung MS, Sung JJY . Global temporal patterns of \\npancreatic cancer and association with socioeconomic development. Sci Rep. 2017;7(1):3165. \\ndoi:10.1038/s41598-017-02997-2 [PubMed: 28600530] \\n11. Rawla P, Sunkara T, Gaduputi V . Epidemiology of pancreatic cancer: global trends, etiology and'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='doi:10.1038/s41598-017-02997-2 [PubMed: 28600530] \\n11. Rawla P, Sunkara T, Gaduputi V . Epidemiology of pancreatic cancer: global trends, etiology and \\nrisk factors. World J Oncol. 2019;10(1):10–27. doi:10.14740/wjon1166 [PubMed: 30834048] Park et al. Page 12\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='12. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS. K-ras mutation in focal proliferative \\nlesions of human pancreas. Cancer Epidemiol Biomarkers Prev. 1998;7(6):515–521. [PubMed: \\n9641496] \\n13. Konstantinidis IT, Vinuela EF, Tang LH, et al. Incidentally discovered pancreatic intraepithelial \\nneoplasia: what is its clinical significance? Ann Surg Oncol. 2013;20(11):3643–3647. doi:10.1245/\\ns10434-013-3042-2 [PubMed: 23748606] \\n14. Oyama H, Tada M, Takagi K, et al. Long-term risk of malignancy in branch-\\nduct intraductal papillary mucinous neoplasms. Gastroenterology. 2020;158(1):226–237.e5. \\ndoi:10.1053/j.gastro.2019.08.032 [PubMed: 31473224] \\n15. Tanaka M, Chari S, Adsay V , et al. ; International Association of Pancreatology. International \\nconsensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous \\ncystic neoplasms of the pancreas. Pancreatology. 2006;6(1–2):17–32. doi:10.1159/000090023 \\n[PubMed: 16327281] \\n16. Hackert T, Fritz S, Klauss M, et al. Main-duct intraductal papillary mucinous neoplasm: \\nhigh cancer risk in duct diameter of 5 to 9mm. Ann Surg. 2015;262(5):875–880. doi:10.1097/\\nSLA.0000000000001462 [PubMed: 26583679] \\n17. Vege SS, Ziring B, Jain R, et al. American Gastroenterological Association Institute guideline \\non the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. \\n2015;148(4):819–822. doi:10.1053/j.gastro.2015.01.015 [PubMed: 25805375] \\n18. Owens DK, Davidson KW, Krist AH, et al. ; US Preventive Services Task Force. Screening for \\npancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. \\nJAMA. 2019;322(5):438–444. doi:10.1001/jama.2019.10232 [PubMed: 31386141] \\n19. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an \\nanalysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. \\n2012; 23(7):1880–1888. doi:10.1093/annonc/mdr541 [PubMed: 22104574] \\n20. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic \\ncancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535–545. doi:10.1007/\\ns00423-007-0266-2 [PubMed: 18193270] \\n21. Wang YT, Gou YW, Jin WW, Xiao M, Fang HY . Association between alcohol intake and the risk \\nof pancreatic cancer: a dose-response meta-analysis of cohort studies. BMC Cancer. 2016;16:212. \\ndoi:10.1186/s12885-016-2241-1 [PubMed: 26968702] \\n22. Genkinger JM, Spiegelman D, Anderson KE, et al. Alcohol intake and pancreatic cancer risk: \\na pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009;18(3):765–\\n776. doi:10.1158/1055-9965.EPI-08-0880 [PubMed: 19258474] \\n23. Johansen D, Stocks T, Jonsson H, et al. Metabolic factors and the risk of pancreatic \\ncancer: a prospective analysis of almost 580,000 men and women in the Metabolic \\nSyndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2307–2317. \\ndoi:10.1158/1055-9965.EPI-10-0234 [PubMed: 20826833] \\n24. Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the \\nUSA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4(3):e137–e147. \\ndoi:10.1016/S2468-2667(18)30267-6 [PubMed: 30733056] \\n25. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently \\nsporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382–3390. doi:10.1200/\\nJCO.2017.72.3502 [PubMed: 28767289] \\n26. Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer \\npredisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401–2409. doi:10.1001/\\njama.2018.6228 [PubMed: 29922827] \\n27. Golan T, Kindler HL, Park JO, et al. Geographic and ethnic heterogeneity of germline BRCA1  or \\nBRCA2  mutation prevalence among patients with metastatic pancreatic cancer screened for entry \\ninto the POLO trial. J Clin Oncol. 2020;38(13):1442–1454. doi:10.1200/JCO.19.01890 [PubMed:'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='BRCA2  mutation prevalence among patients with metastatic pancreatic cancer screened for entry \\ninto the POLO trial. J Clin Oncol. 2020;38(13):1442–1454. doi:10.1200/JCO.19.01890 [PubMed: \\n32073954] \\n28. Hu C, LaDuca H, Shimelis H, et al. Multigene hereditary cancer panels reveal high-risk pancreatic \\ncancer susceptibility genes. JCO Precis Oncol. 2018;2. doi:10.1200/po.17.00291Park et al. Page 13\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='29. Hu ZI, Hellmann MD, Wolchok JD, et al. Acquired resistance to immunotherapy in MMR-D \\npancreatic cancer. Journal Immunother Cancer. 2018;6(1):127. doi:10.1186/s40425-018-0448-1\\n30. Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O’Reilly EM. An emerging paradigm for \\ngermline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical \\npractice: a review. JAMA Oncol. 2020;6(5):764–771. doi:10.1001/jamaoncol.2019.5963 [PubMed: \\n32053139] \\n31. Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage \\npancreatic intraepithelial neoplasia. Gastroenterology. 2012; 142(4):730–733.e9. doi:10.1053/\\nj.gastro.2011.12.042 [PubMed: 22226782] \\n32. Waddell N, Pajic M, Patch AM, et al. ; Australian Pancreatic Cancer Genome Initiative. Whole \\ngenomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–\\n501. doi:10.1038/nature14169 [PubMed: 25719666] \\n33. Aguirre AJ, Nowak JA, Camarda ND, et al. Real-time genomic characterization of \\nadvanced pancreatic cancer to enable precision medicine. Cancer Discov. 2018;8(9):1096–1111. \\ndoi:10.1158/2159-8290.CD-18-0275 [PubMed: 29903880] \\n34. Bailey P, Chang DK, Nones K, et al. ; Australian Pancreatic Cancer Genome Initiative. \\nGenomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–\\n52. doi:10.1038/nature16965 [PubMed: 26909576] \\n35. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and \\nstroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–\\n1178. doi:10.1038/ng.3398 [PubMed: 26343385] \\n36. Hayashi A, Fan J, Chen R, et al. A unifying paradigm for transcriptional heterogeneity \\nand squamous features in pancreatic ductal adenocarcinoma. Nature Cancer. 2020;1(1):59–74. \\ndoi:10.1038/s43018-019-0010-1 [PubMed: 35118421] \\n37. Aung KL, Fischer SE, Denroche RE, et al. Genomics-driven precision medicine for advanced \\npancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–\\n1354. doi:10.1158/1078-0432.CCR-17-2994 [PubMed: 29288237] \\n38. Knox JJClinical advances in pancreas adenocarcinoma. Cancer Res. 2020;80(22 suppl). AACR \\nVirtual Special Conference on Pancreatic Cancer abstract IA-08.\\n39. Lowery MA, Jordan EJ, Basturk O, et al. Real-time genomic profiling of pancreatic ductal \\nadenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res. \\n2017;23(20):6094–6100 [PubMed: 28754816] \\n40. Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic \\ncancer receiving matched therapies following molecular profiling: a retrospective analysis \\nof the Know Your Tumor registry trial. Lancet Oncol. 2020;21(4):508–518. doi:10.1016/\\nS1470-2045(20)30074-7 [PubMed: 32135080] \\n41. Balachandran VP, Łuksza M, Zhao JN, et al. ; Australian Pancreatic Cancer Genome Initiative; \\nGarvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; \\nUniversity of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; \\nUniversity of Melbourne, Centre for Cancer Research; University of Queensland, Institute for \\nMolecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, \\nChris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; \\nRoyal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria \\nHospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied \\nResearch on Cancer. Identification of unique neoantigen qualities in long-term survivors \\nof pancreatic cancer. Nature. 2017;551(7681):512–516. doi:10.1038/nature24462 [PubMed: \\n29132146] \\n42. Beatty GL, Eghbali S, Kim R. Deploying immunotherapy in pancreatic cancer: defining \\nmechanisms of response and resistance. Am Soc Clin Oncol Educ Book. 2017;37:267–278. \\ndoi:10.1200/EDBK_175232 [PubMed: 28561678]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='mechanisms of response and resistance. Am Soc Clin Oncol Educ Book. 2017;37:267–278. \\ndoi:10.1200/EDBK_175232 [PubMed: 28561678] \\n43. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and \\nPD-L1. Cancer Res. 2015;75(11):2139–2145. doi:10.1158/0008-5472.CAN-15-0255 [PubMed: \\n25977340] \\n44. Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed \\ndeath ligand 1 expression, and tumor mutational burden predict efficacy in patients treated Park et al. Page 14\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327. \\ndoi:10.1200/JCO.2018.78.2276 [PubMed: 30557521] \\n45. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for \\nlocally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–833. \\ndoi:10.1097/CJI.0b013e3181eec14c [PubMed: 20842054] \\n46. Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer: \\nclinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527–540. doi:10.1038/\\ns41571-020-0363-5 [PubMed: 32398706] \\n47. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel \\ntherapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17(2):108–123. \\ndoi:10.1038/s41571-019-0281-6 [PubMed: 31705130] \\n48. Walter FM, Mills K, Mendonça SC, et al. Symptoms and patient factors associated with \\ndiagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort \\nstudy. Lancet Gastroenterol Hepatol. 2016;1(4):298–306. doi:10.1016/S2468-1253(16)30079-6 \\n[PubMed: 28404200] \\n49. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on pancreas cancer screening \\nin high-risk individuals: expert review. Gastroenterology. 2020;159(1):358–362. doi:10.1053/\\nj.gastro.2020.03.088 [PubMed: 32416142] \\n50. Wang XY , Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment \\nof resectability and metabolic response of pancreatic cancer. World J Gastroenterol. \\n2014;20(42):15580–15589. doi:10.3748/wjg.v20.i42.15580 [PubMed: 25400441] \\n51. Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19–9 represents a \\nmarker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. \\nHPB (Oxford). 2014;16(5):430–438. doi:10.1111/hpb.12154 [PubMed: 23991810] \\n52. Fahrmann JF, Schmidt CM, Mao X, et al. Lead-time trajectory of CA19–9 as an anchor marker \\nfor pancreatic cancer early detection. Gastroenterology. 2021;160(4):1373–1383. doi:10.1053/\\nj.gastro.2020.11.052 [PubMed: 33333055] \\n53. Lee J-S, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal \\nadenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol. \\n2019;13(8):1623–1650. doi:10.1002/1878-0261.12537 [PubMed: 31243883] \\n54. Vauthey JN, Dixon E. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline \\nResectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol. \\n2009;16(7):1725–1726. doi:10.1245/s10434-009-0409-5 [PubMed: 19396495] \\n55. Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional validation study of the \\nAmerican Joint Commission on Cancer (8th Edition) changes for T and N staging \\nin patients with pancreatic adenocarcinoma. Ann Surg. 2017;265(1):185–191. doi:10.1097/\\nSLA.0000000000001763 [PubMed: 27163957] \\n56. Gilbert JW, Wolpin B, Clancy T, et al. Borderline resectable pancreatic cancer: conceptual \\nevolution and current approach to image-based classification. Ann Oncol. 2017;28(9):2067–2076. \\ndoi:10.1093/annonc/mdx180 [PubMed: 28407088] \\n57. Schmidt CM, Turrini O, Parikh P, et al. Effect of hospital volume, surgeon experience, and surgeon \\nvolume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch \\nSurg. 2010;145(7):634–640. doi:10.1001/archsurg.2010.118 [PubMed: 20644125] \\n58. Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, et al. Minimally-invasive vs open \\npancreaticoduodenectomy: systematic review and meta-analysis. J Am Coll Surg. \\n2014;218(1):129–139. doi:10.1016/j.jamcollsurg.2013.09.005 [PubMed: 24275074] \\n59. de Rooij T, Lu MZ, Steen MW, et al. ; Dutch Pancreatic Cancer Group. Minimally invasive versus \\nopen pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and \\nregistry studies. Ann Surg. 2016;264(2):257–267. doi:10.1097/SLA.0000000000001660 [PubMed: \\n26863398]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='open pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and \\nregistry studies. Ann Surg. 2016;264(2):257–267. doi:10.1097/SLA.0000000000001660 [PubMed: \\n26863398] \\n60. Ramacciato G, Nigri G, Petrucciani N, et al. Pancreatectomy with mesenteric and portal vein \\nresection for borderline resectable pancreatic cancer: multicenter study of 406 patients. Ann Surg \\nOncol. 2016;23(6):2028–2037. doi:10.1245/s10434-016-5123-5 [PubMed: 26893222] Park et al. Page 15\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='61. Moffat GT, Epstein AS, O’Reilly EM. Pancreatic cancer: a disease in need: optimizing and \\nintegrating supportive care. Cancer. 2019;125(22): 3927–3935. doi:10.1002/cncr.32423 [PubMed: \\n31381149] \\n62. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term \\noutcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. \\nJAMA. 2013;310(14):1473–1481. doi:10.1001/jama.2013.279201 [PubMed: 24104372] \\n63. Neoptolemos JP, Stocken DD, Bassi C, et al. ; European Study Group for Pancreatic Cancer. \\nAdjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic \\ncancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–1081. doi:10.1001/\\njama.2010.1275 [PubMed: 20823433] \\n64. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and \\ncapecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer \\n(ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–\\n1024. doi:10.1016/s0140-6736(16)32409-6 [PubMed: 28129987] \\n65. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in \\npatients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. \\nJAMA. 2007;297(3):267–277. doi:10.1001/jama.297.3.267 [PubMed: 17227978] \\n66. Neoptolemos JP, Palmer DH, Ghaneh P, et al. ; European Study Group for Pancreatic Cancer. \\nComparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients \\nwith resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. \\nLancet. 2017;389(10073):1011–1024. doi:10.1016/S0140-6736(16)32409-6 [PubMed: 28129987] \\n67. Wang-Gillam A, Li CP, Bodoky G, et al. ; NAPOLI-1 Study Group. Nanoliposomal \\nirinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous \\ngemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. \\n2016;387(10018):545–557. doi:10.1016/S0140-6736(15)00986-1 [PubMed: 26615328] \\n68. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after \\ncurative resection of cancer of the pancreas and periampullary region: phase III trial of \\nthe EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–782. \\ndoi:10.1097/00000658-199912000-00006 [PubMed: 10615932] \\n69. Neoptolemos JP, Stocken DD, Friess H, et al. ; European Study Group for Pancreatic Cancer. A \\nrandomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N \\nEngl J Med. 2004;350(12):1200–1210. doi:10.1056/NEJMoa032295 [PubMed: 15028824] \\n70. Murphy JE, Wo JY , Ryan DP, et al. Total neoadjuvant therapy with folfirinox followed by \\nindividualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase \\n2 clinical trial. JAMA Oncol. 2018;4(7):963–969. doi:10.1001/jamaoncol.2018.0329 [PubMed: \\n29800971] \\n71. Chawla A, Molina G, Pak LM, et al. Neoadjuvant therapy is associated with improved survival \\nin borderline-resectable pancreatic cancer. Ann Surg Oncol. 2020;27(4):1191–1200. doi:10.1245/\\ns10434-019-08087-z [PubMed: 31802297] \\n72. Jang JY , Han Y , Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with \\ngemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a \\nprospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–222. \\ndoi:10.1097/SLA.0000000000002705 [PubMed: 29462005] \\n73. Katz MHG, Ou FS, Herman JM, et al. ; Alliance for Clinical Trials on Oncology. Alliance for \\nclinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. \\nchemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma \\nof the head of the pancreas. BMC Cancer. 2017;17(1):505. doi:10.1186/s12885-017-3441-z \\n[PubMed: 28750659]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='of the head of the pancreas. BMC Cancer. 2017;17(1):505. doi:10.1186/s12885-017-3441-z \\n[PubMed: 28750659] \\n74. Versteijne E, Suker M, Groothuis K, et al. ; Dutch Pancreatic Cancer Group. Preoperative \\nchemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic \\ncancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. \\n2020;38(16):1763–1773. doi:10.1200/JCO.19.02274 [PubMed: 32105518] \\n75. Loehrer PJ Sr, Feng Y , Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy \\nin patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. \\nJ Clin Oncol. 2011;29(31): 4105–4112. doi:10.1200/JCO.2011.34.8904 [PubMed: 21969502] Park et al. Page 16\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='76. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: \\ncomparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy \\nalone. J Natl Cancer Inst. 1988;80 (10):751–755. doi:10.1093/jnci/80.10.751 [PubMed: 2898536] \\n77. Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX \\nor mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable \\n(BR) adenocarcinoma of the pancreas. J Clin Oncol. 2021; 39(3_suppl):377. doi:10.1200/\\nJCO.2021.39.3_suppl.377\\n78. van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of \\nthe head of the pancreas. N Engl J Med. 2010;362(2):129–137. doi:10.1056/NEJMoa0903230 \\n[PubMed: 20071702] \\n79. Pancreatic Cancer, Version 1.2021. National Comprehensive Cancer Network; 2020.\\n80. Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on \\nthe management of locally advanced pancreatic cancer using radiation/combined modality therapy. \\nBr J Cancer. 2007;96(8):1183–1190. doi:10.1038/sj.bjc.6603719 [PubMed: 17406358] \\n81. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based \\nchemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, \\nphase 2 trial. Lancet Oncol. 2013;14(4):317–326. doi:10.1016/S1470-2045(13)70021-4 [PubMed: \\n23474363] \\n82. Glazer ES, Hornbrook MC, Krouse RS. A meta-analysis of randomized trials: immediate stent \\nplacement vs. surgical bypass in the palliative management of malignant biliary obstruction. J \\nPain Symptom Manage. 2014;47(2):307–314. doi:10.1016/j.jpainsymman.2013.03.013 [PubMed: \\n23830531] \\n83. Uemura S, Iwashita T, Iwata K, et al. Endoscopic duodenal stent versus surgical gastrojejunostomy \\nfor gastric outlet obstruction in patients with advanced pancreatic cancer. Pancreatology. 2018; \\n18(5):601–607. doi:10.1016/j.pan.2018.04.015 [PubMed: 29753623] \\n84. Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination \\ndeficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. \\n2020;26(13):3239–3247. doi:10.1158/1078-0432.CCR-20-0418 [PubMed: 32444418] \\n85. Florou V , Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna \\nI. Treatment rechallenge with checkpoint inhibition in patients with mismatch repair-deficient \\npancreatic cancer after planned treatment interruption. JCO Precis Oncol. 2020;4(4):780–784. \\ndoi:10.1200/PO.20.00052\\n86. Varghese AM, Singh I, Singh R, et al. Early-onset pancreas cancer: clinical descriptors, genomics, \\nand outcomes. J Natl Cancer Inst. 2021; djab038. doi:10.1093/jnci/djab038\\n87. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers \\nin adults and children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448 \\n[PubMed: 29466156] \\n88. Heining C, Horak P, Uhrig S, et al. NRG1  Fusions in KRAS  Wild-Type Pancreatic Cancer. Cancer \\nDiscov. 2018;8(9):1087–1095. doi:10.1158/2159-8290.CD-18-0036 [PubMed: 29802158] \\n89. O’Reilly EM, Oh DY , Dhani N, et al. Durvalumab with or without tremelimumab for patients with \\nmetastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. \\n2019;5(10):1431–1438. doi:10.1001/jamaoncol.2019.1588 [PubMed: 31318392] \\n90. O’Hara MH, O’Reilly EM, Varadhachary G, et al. CD40 agonistic monoclonal antibody \\nAPX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of \\nmetastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. \\n2021;22 (1):118–131. doi:10.1016/S1470-2045(20)30532-5 [PubMed: 33387490] \\n91. Bendell JC, Manji GA, Pant S, et al. A phase I study to evaluate the safety and tolerability \\nof AB680 combination therapy in participants with gastrointestinal malignancies. J Clin Oncol.'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='91. Bendell JC, Manji GA, Pant S, et al. A phase I study to evaluate the safety and tolerability \\nof AB680 combination therapy in participants with gastrointestinal malignancies. J Clin Oncol. \\n2020;38 (4_suppl):TPS788. doi:10.1200/JCO.2020.38.4_suppl.TPS788Park et al. Page 17\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 17}, page_content='Box.\\nOverview of Pancreatic Cancer\\nGeneral Facts\\nApproximately 60 000 diagnoses per year in the US\\nIncidence of about 1% over lifetime\\nThe tenth to eleventh leading cause of cancer in the US\\nThird leading cause of cancer-related mortality\\n5-year survival (all-comers), 10%\\nMedian age at diagnosis, 71 years\\nMale/female incidence ratio: 1.3/1.0\\n50% of patients present with metastatic disease (AJCC stage IV)\\n30% of patients present with locally advanced disease (AJCC stage III)\\n20% of patients present with localized resectable disease (AJCC stage I and II)\\nMost common causative germline alterations: BRCA2, BRCA1, ATM, PALB2\\nCommon sites of metastasis: liver, lymph node, lung, and peritoneum\\nRare sites of metastasis: skin, brain, and leptomeninges\\nLifestyle Risk Factors\\nTobacco\\nExcess alcohol consumption (chronic pancreatitis)\\nObesity (body mass index >30), metabolic disorders, low levels of physical activity\\nDiet: high fat, polyunsaturated fats, processed meats\\nGenetic Risk Factors  a \\nHereditary breast and ovary cancer syndrome ( BRCA1/2 , PALB2 ; 5%–9%)\\nAtaxia-telangiectasia ( ATM ; approximately 3%–4%)\\nFamilial atypical multiple mole and melanoma syndrome ( CDKN2A , p16; <1%)\\nLynch syndrome ( MLH1 , MSH2 , MSH6 , PMS2 , EPCAM ; <1%)\\nHereditary pancreatitis ( PRSS1 , SPINK1 ; <1%)\\nPeutz-Jeghers syndrome ( STK11 ; <1%)\\nAbbreviation: AJCC, American Joint Committee on Cancer.\\naPercentages indicate the frequency per 100 unselected patients diagnosed with pancreas cancer.Park et al. Page 18\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 18}, page_content='Figure 1. \\nSpectrum of Localized Pancreatic CancerPark et al. Page 19\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 19}, page_content='Figure 2. \\nNovel Targets and Agents in Development in Pancreatic Cancer\\nADB indicates adenosine diphosphate; CA, carbohydrate antigen;\\nCEA, carcinoembryonic antigen; CSF, colony-stimulating factor; DDR, DNA damage repair, \\nEGFR, epidermal growth factor receptor; ILC, innate lymphoid cell; and T H1, type 1 helper \\nT cell.\\na Approved by the US Food and Drug Administration or guideline-endorsed for pancreatic \\ncancer.Park et al. Page 20\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 20}, page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptPark et al. Page 21Table 1.\\nOverview of Treatment and Prognosis by Stage of Pancreatic Cancer\\nDisease extent Localized Advanced\\nMajor vasculature involvementa Uninvolved or abutted Uninvolved or abutted Encased Distant metastasis, \\nirrespective of the major \\nvascular involvement\\nClinical stage Resectable Borderline resectable Locally advanced Metastatic\\nPrevalence of pancreatic cancer among patients \\nnewly diagnosed with PDAC, %10–15 30–35 30–35 50–55\\nAmerican Joint Committee on Cancer tumor, \\nnode, and metastasis stageI-II II-III II-III IV\\nTreatment intent Curative Curative Supportive and palliative Supportive and palliative\\nTreatment Surgery plus adjuvant \\nsystemic therapyNeoadjuvant systemic therapy; surgery \\nfor resectable patients from favorable \\nresponse; radiation for unresectable \\npatients without distant metastasisNeoadjuvant systemic therapy; surgery \\nfor resectable patients from favorable \\nresponse; radiation for unresectable \\npatients without distant metastasisSystemic therapya\\n5-y survival rate, % 35–45 10–15 10–15 <5\\nAbbreviation: PDAC, pancreatic ductal adenocarcinoma.aThe degree of contact between the tumor and local blood vessels (ie, the superior mesenteric and portal veins as well as the celiac, hepatic, and superior mesenteric arteries) is categorized as either \\nuninvolved, abutted, or encased. Abutment implies that the tumor has 180° or less of blood vessel involvement and encasement implies greater than 180° of circumferential tumor-vessel involvement.\\nJAMA . Author manuscript; available in PMC 2022 August 09.'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 21}, page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptPark et al. Page 22Table 2.\\nSummary of Selected Clinical Trials of Systemic Therapy for Pancreatic Cancer\\nTrial Setting of therapy Study regimenComparator \\nregimenRandomized \\npatients, No.Primary end \\npointMedian \\nsurvival, moCommon serious adverse eventsa reported in \\nstudy group (% of patients)\\nCONKO-00165 \\n(2007)Adjuvant Gemcitabine Observation 368 Disease-free \\nsurvival13.4 vs 6.7 Leukopenia (2), anemia (1), thrombocytopenia \\n(1), nausea/vomiting (1), hepatic dysfunction \\n(1), diarrhea (1)\\nESPAC-466 (2017) Adjuvant Gemcitabine and \\ncapecitabineGemcitabine 730 Overall survival 28.0 vs 25.5 Neutropenia (38), leukopenia (10), hand-foot \\nsyndrome (7), fatigue (6), diarrhea (5)\\nPRODIGE-245 \\n(2018)Adjuvant mFOLFIRINOX Gemcitabine 493 Overall survival 54.4 vs 35 Neutropenia (28), diarrhea (19), paresthesia \\n(13), fatigue (11), sensory peripheral \\nneuropathy (9), nausea (6), hepatic dysfunction \\n(<5)\\nPRODIGE3 (2011) First-line for \\nmetastatic diseaseFOLFIRINOX Gemcitabine 342 Overall survival 11.1 vs 6.8 Neutropenia (46), fatigue (24), vomiting \\n(15), diarrhea (13), thrombocytopenia (9), \\nsensory neuropathy(9), hepatic dysfunction (7), \\nthromboembolism (7), anemia (8)\\nMPACT4 (2013) First-line for \\nmetastatic diseaseGemcitabine and \\nalbumin-bound \\npaclitaxelGemcitabine 861 Overall survival 8.5 vs 6.7 Neutropenia (38), leukopenia (31), \\nthrombocytopenia (13), anemia (13), fatigue \\n(17), peripheral neuropathy (17), diarrhea (6)\\nNAPOLI-167 (2015) For metastatic \\ndisease after \\nprogression on \\ngemcitabine therapy5-FU/LV and \\nnanoliposomal \\nirinotecan5-FU/LV 417 Overall survival 6.2 vs 4.2 Neutropenia (27), fatigue (14), diarrhea (13), \\nvomiting (11), anemia (9)\\nPOLO8 (2019) Maintenance \\nfollowing ≥4 mo \\nof platinum-based \\ntherapy (germline BRCA1/2 )Olaparib Placebo 154 Progression-free \\nsurvival7.4 vs 3.8 Anemia (11), fatigue (5), decreased appetite (3), \\nabdominal pain (2), vomiting (1), arthralgia (1)\\nAbbreviations: 5-FU/LV , fluorouracil, leucovorin; mFOLFIRINOX, modified FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin).aGrade 3 or higher.\\nJAMA . Author manuscript; available in PMC 2022 August 09.')]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# `pages` contains a list of 28 Document object\n",
    "\n",
    "# Here's Page 18:\n",
    "# Document(\n",
    "#   metadata={'source': './documents/nihms-1828057.pdf', 'page': 18}, \n",
    "#   page_content='Figure 1. \\nSpectrum of Localized Pancreatic CancerPark et al. Page 19\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'\n",
    "# )\n",
    "\n",
    "pages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import the class RecursiveCharacterTextSplitter from the package langchain.text_splitter\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create an instance of RecursiveCharacterTextSplitter with:\n",
    "# - chunk_size...: 1000 (max number of characters per chunk)\n",
    "# - chunk_overlap:   20 (number of characters to overlap between chunks)\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=20)\n",
    "\n",
    "# Example with chunk_size=8 and chunk_overlap=3\n",
    "# Data...: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ \n",
    "# Chunk-1: _ _ _ _ _ _ _ _  \n",
    "# Chunk-2:           _ _ _ _ _ _ _ _\n",
    "# Chunk-3:                     _ _ _ _ _ _ _ _ \n",
    "# Chunk-4:                               _ _ _ _ _ _ _ _\n",
    "# Chunk-5:                                         _ _ _ _ _ _ _ _\n",
    "# Chunk-6:                                                   _ _ _ _ _\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Now split the pages of the PDF file\n",
    "documents = text_splitter.split_documents(pages)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 0}, page_content='Pancreatic Cancer: A Review\\nWungki Park, MD ,\\nDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York\\nDavid M. Rubenstein Center for Pancreatic Cancer Research, New York, New York\\nDepartment of Medicine, Weill Cornell Medical College, New York, New York\\nParker Institute for Cancer Immunotherapy, San Francisco, California\\nAkhil Chawla, MD ,\\nDepartment of Surgery, Northwestern Medicine Regional Medical Group, Northwestern University \\nFeinberg School of Medicine, Chicago, Illinois\\nRobert H. Lurie Comprehensive Cancer Center, Chicago, Illinois\\nEileen M. O’Reilly, MD\\nDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York\\nDavid M. Rubenstein Center for Pancreatic Cancer Research, New York, New York\\nDepartment of Medicine, Weill Cornell Medical College, New York, New York\\nAbstract\\nIMPORTANCE— Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer,'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 0}, page_content='with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC \\nis increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of \\ncancer-related mortality by 2030.\\nOBSERVATIONS— Effective screening is not available for PDAC, and most patients \\npresent with locally advanced (30%–35%) or metastatic (50%–55%) disease at diagnosis. A \\nmultidisciplinary management approach is recommended. Localized pancreas cancer includes \\nresectable, borderline resectable (localized and involving major vascular structures), and locally \\nadvanced (unresectable) disease based on the degree of arterial and venous involvement \\nby tumor, typically of the superior mesenteric vessels. For patients with resectable disease \\nat presentation (10%–15%), surgery followed by adjuvant chemotherapy with FOLFIRINOX \\nCorresponding Author:  Eileen M. O’Reilly, MD, Memorial Sloan Kettering Cancer Center, 300 E 66th St, Office 1021, New York,'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 0}, page_content='NY 10065 (oreillye@mskcc.org).\\nAuthor Contributions:  Dr O’Reilly had full access to all of the data in the study and takes responsibility for the integrity of the data \\nand the accuracy of the data analysis.\\nConcept and design:  All authors.\\nAcquisition, analysis, or interpretation of data:  All authors.\\nDrafting of the manuscript:  All authors.\\nCritical revision of the manuscript for important intellectual content:  All authors.\\nObtained funding:  Park, O’Reilly.\\nAdministrative, technical, or material support:  Park, O’Reilly.\\nSupervision:  O’Reilly.\\nOther - involved in writing:  Chawla.\\nHHS Public Access\\nAuthor manuscript\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nPublished in final edited form as:\\nJAMA . 2021 September 07; 326(9): 851–862. doi:10.1001/jama.2021.13027.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 1}, page_content='(fluorouracil, irinotecan, leucovorin, oxaliplatin) represents a standard therapeutic approach with \\nan anticipated median overall survival of 54.4 months, compared with 35 months for single-agent \\ngemcitabine (stratified hazard ratio for death, 0.64 [95% CI, 0.48–0.86]; P = .003). Neoadjuvant \\nsystemic therapy with or without radiation followed by evaluation for surgery is an accepted \\ntreatment approach for resectable and borderline resectable disease. For patients with locally \\nadvanced and unresectable disease due to extensive vascular involvement, systemic therapy \\nfollowed by radiation is an option for definitive locoregional disease control. For patients with \\nadvanced (locally advanced and metastatic) PDAC, multiagent chemotherapy regimens, including \\nFOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil, all have \\na survival benefit of 2 to 6 months compared with a single-agent gemcitabine. For the 5% to'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 1}, page_content='7% of patients with a BRCA  pathogenic germline variant and metastatic PDAC, olaparib, a \\npoly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that \\nimproves progression-free survival following initial platinum-based therapy.\\nCONCLUSIONS AND RELEVANCE— Approximately 60 000 new cases of PDAC are \\ndiagnosed per year, and approximately 50% of patients have advanced disease at diagnosis. The \\nincidence of PDAC is increasing. Currently available cytotoxic therapies for advanced disease \\nare modestly effective. For all patients, multidisciplinary management, comprehensive germline \\ntesting, and integrated supportive care are recommended.\\nApproximately 60 430 new diagnoses of pancreatic cancer are anticipated in the US in \\n2021.1 The incidence is rising at a rate of 0.5% to 1.0% per year, and pancreatic cancer \\nis projected to become the second-leading cause of cancer death by 2030 in the US.1,2'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 1}, page_content='Pancreatic ductal adenocarcinoma (PDAC) accounts for the majority (90%)of pancreatic \\nneoplasms, and the other subtypes include acinar carcinoma, pancreaticoblastoma, and \\nneuroendocrine tumors. Most patients with pancreatic cancer present with nonspecific \\nsymptoms at an advanced stage with disease that is not amenable to curative surgery.1 \\nNo effective screening exists. The 5-year survival rate approached 10% for the first time in \\n2020, compared with 5.26% in 2000.1 The survival improvements have been modest and \\nattributed primarily to multiagent cytotoxic therapies.3–5 Recently, comprehensive germline \\nand somatic genomic sequencing became standard of care for small subgroups of patients \\nwith targeted treatment opportunities.6,7 Olaparib, a poly (adenosine diphosphate[ADB]-\\nribose) polymerase inhibitor, can prolong cancer control in patients with a BRCA1/2 \\npathogenic germline variant.8,9 This review summarizes current evidence regarding'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 1}, page_content='pathobiology, diagnosis, and management of PDAC.\\nMethods\\nA PubMed search was performed for English-language articles describing randomized \\nclinical trials, meta-analyses, and systematic reviews of pancreatic cancer published between \\nJanuary 1, 2010, and July 5, 2021. We identified 43 randomized clinical trials, 85 meta-\\nanalyses, and 171 systematic reviews. The authors selected articles for inclusion, prioritizing \\nrecent randomized clinical trials of higher quality based on rigor of study design, adequate \\nsample size, and long-term follow-up. A total of 24 randomized clinical trials, 4 meta-\\nanalyses, 3 systematic reviews, 5 guideline recommendations, and 37 observational and \\ncohort studies, including publications prior to 2010, were included.Park et al. Page 2\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 2}, page_content='Epidemiology and Screening\\nPDAC is the third-leading cause of cancer mortality in the US and the seventh-leading cause \\nworldwide (Box).10The median age at diagnosis in the US is 71 years, and PDAC is slightly \\nmore common in men than in women (5.5 vs 4.0 per 100 000 individuals).11At presentation, \\n50% of patients have metastatic disease, 10% to 15% have localized disease amenable to \\nsurgery, and the remainder (30%–35%) have locally advanced mostly unresectable disease \\ndue to the extent of tumor-vascular involvement.1 Pancreatic intraepithelial neoplasms \\n(PanINs) refer to precancerous lesions, of which a small fraction may progress to high-grade \\ndysplasia and PDAC.12 Low-grade PanINs are common and their potential to transform \\ninto a malignancy is unclear. In a retrospective review of 584 patients who underwent a \\npancreatectomy for non-PDAC (median age, 59 years), 153 patients (26%) were identified'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 2}, page_content='with PanINs; most patients had low-grade PanIN-1 (50%) or PanIN-2 (41%) and 13 (8%) \\nhad PanIN-3. None of the patients with PanIN-3 developed cancer, whereas 1 patient with \\nPanIN-1B developed cancer in 4.4 years.13 Intraductal papillary mucinous neoplasms are \\nmore common precancerous cystic lesions than PanINs and can arise in either the main \\nor branch pancreatic duct. In a cohort study of 605 patients who underwent a surgical \\nprocedure for intraductal papillary mucinous neoplasms, the malignancy rate for final \\npathology in main-duct intraductal papillary mucinous neoplasms was 68%, whereas in \\na different cohort study of 1404 patients with branch-duct intraductal papillary mucinous \\nneoplasms, only 15% evolved to PDAC over 15 years.14–16 Annual imaging surveillance \\nis recommended; however, there is no consensus as to the optimal surveillance method or \\nfrequency of assessment.15,17 For asymptomatic average-risk individuals, the US Preventive'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 2}, page_content='Services Task Force recommends against routine screening for PDAC.18\\nModifiable and Inherited Risk Factors\\nAmong lifestyle risk factors, current cigarette smoking has the strongest association \\nwith PDAC. A meta-analysis of 12 case-control studies that included 6507 patients with \\npancreatic cancer and 12 890 control patients reported an odds ratio (OR) of 1.74 (95% CI, \\n1.61–1.87) for the association of current smoking with pancreatic cancer (absolute rates not \\nreported).19,20 There was also a modest association of alcohol use with PDAC, when intake \\nexceeded 30 g per day (approximately 3 drinks per day), according to a meta-analysis of 19 \\nprospective studies reporting outcomes from 4 211 129 individuals (relative risk, 1.22 [95% \\nCI, 1.03–1.45]; absolute rates not reported).21 Chronic pancreatitis was associated with a \\n13-fold increased risk for PDAC in a pooled analysis of 14 prospective cohort studies of'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 2}, page_content='862 664 individuals (relative risk, 13.3 [95% CI, 6.1–28.9]).22 Obesity, defined as a body \\nmass index in the fifth quintile (highest 20%), was also associated with an increased risk \\nof PDAC (incidence, 14.1 vs 5.7 per 100 000 person-years; adjusted relative risk, 1.54 \\n[95% CI, 1.04–2.29]) in a Norwegian analysis of 940 060 individuals.23 Diets of processed \\nmeat, high-fructose beverages, and saturated fat were associated with obesity, diabetes, and \\npancreatic cancer.24 The incidence of PDAC in people younger than 30 years is increasing. \\nThe annual incidence of PDAC increased with younger age from 1995 to 2014, from 0.77% \\n(95% CI, 0.57%–0.98%) for those aged 45 to 49 years, to 2.47% (95% CI, 1.77%–3.18%) \\nfor those aged 30 to 34 years, to 4.34% (95% CI, 3.19%–5.50%) for those aged 25 to 29 \\nyears, consistent with an increase in younger patients.24 This observation may be related Park et al. Page 3\\nJAMA . Author manuscript; available in PMC 2022 August 09.'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 2}, page_content='Author Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 3}, page_content='to increasing rates of obesity and diabetes, which are potentially modifiable risk factors for \\nPDAC.\\nAbout 3.8% to 9.7% of patients with PDAC have pathogenic germline gene variants \\nthat increase susceptibility to PDAC. These variants occur mostly in DNA damage repair \\ngenes.25–27 The most common variants in PDAC include BRCA2 , BRCA1  (hereditary breast \\nand ovary cancer syndrome), and ATM  (ataxia telangiectasia syndrome). Germline BRCA2 \\nvariants are associated with an increased risk for PDAC (OR, 9.07 [95% CI, 6.33–12.98]) \\nmore commonly than BRCA1  (OR, 2.95 [95% CI, 1.49–5.60]) or ATM  variants (OR, \\n8.96 [95% CI, 6.12–12.98]).28 Uncommon (1% of patients with PDAC) but therapeutically \\nimportant inheritable germline variants also occur in PDAC in mismatch repair deficiency \\ngenes MLH1 , MSH2 , MSH6 , and PMS2  as part of Lynch syndrome.29 In 2019, the National \\nComprehensive Cancer Network guidelines recommended that all patients newly diagnosed'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 3}, page_content='with PDAC undergo germline testing with a gene panel including BRCA1/2, ATM, MLH1, \\nMSH2, MSH6 , and PMS2 .30 Healthy family members are also recommended for genetic \\ncounseling if an individual is determined to be at high risk based on the following criteria: \\na first-degree relative with early-onset PDAC (<50 years), more than 1 first-degree family \\nmember with PDAC, or a known pathogenic germline gene variant associated with PDAC. \\nFor optimal genomic testing, a multigene panel is recommended over traditional hierarchical \\nsingle-gene testing for efficiency and cost.30\\nMolecular Profiling of Pancreatic Cancer\\nThe pathophysiology of PDAC is characterized by complex multistep genetic alterations. In \\nthe precancerous state, PanINs acquire cumulative genetic insults resulting in instigating \\noncogenes that are responsible for the initiation and maintenance of PDAC, including \\nKRAS , CDKN2A , TP53 , and SMAD4 .31 KRAS  variants occur as an early step in PDAC'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 3}, page_content='development (low-grade PanINs) and are identified in 90% to 92% of individuals with \\nPDAC. As PanIN progresses to grade 2 or 3, additional gene variants in CDKN2A , \\nTP53 , and/or SMAD4  are acquired.31 Collectively, these genomic alterations contribute \\nto multifaceted defects in tumor suppressor mechanisms resulting in dysregulated growth \\nsignaling and inflammation, which are key aspects of PDAC. Additionally, about 10% to \\n15% of PDACs acquire variants in the SWI/SNF chromatin remodeling genes related to \\nlarge-scale structural genomic aberrations.32\\nRecent advances in molecular pathology and classification of PDAC have affected clinical \\npractice.32–35 One example is subtyping of PDAC into “basal-like” or “classical” type by \\nRNA transcriptional analyses.34–36 The classical subtype of PDAC is characterized by a \\nhigher level of differentiation, fibrosis, and inflammation, whereas the basal-like subtype is'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 3}, page_content='associated with a poorer clinical outcome and loss of differentiation. The value of selecting \\ntherapies based on PDAC subtypes is under investigation in prospective trials.37,38 Whole-\\ngenome structure analysis has provided insight into genomic instability and the relationship \\nwith DNA maintenance genes ( BRCA1/2  and PALB2 ) and, specifically, genetic signature \\n3. These findings suggest that platinum-based therapy and poly (ADP-ribose) polymerase \\ninhibitors may be effective for patients with pathogenic variants in BRCA1/2  and PALB2 .32 Park et al. Page 4\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 4}, page_content='One prospective trial building on these observations has led to the approval of the targeted \\nagent olaparib in select patients with BRCA1/2  pathogenic germline variants.8,9,33,39,40\\nClinical Significance of Immune Tumor Microenvironment\\nPDAC cells exist in an impenetrable network, also known as the tumor microenvironment \\n(TME ), which comprises immune cells, cytokines, metabolites, fibroblast, and desmoplastic \\nstroma rich in hyaluronan. The immunosuppressive TME helps PDAC cells evade host \\nimmune surveillance. A potent host anticancer T cell memory against PDAC neoantigens \\nhas been identified in 82 select long-term survivors of PDAC who lived more than 3 \\nyears after undergoing surgery.41 However, in most patients, the TME suppresses the \\nimmune system and antagonizes host anticancer immunity and promotes carcinogenesis. \\nThe TME of PDAC is characterized by limited infiltration of CD8+ T cells and an'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 4}, page_content='abundance of myeloid derived suppressor cells, tumor-associated macrophages, tumor-\\nassociated neutrophils, and regulatory T cells. Additionally, the extracellular matrix, \\ncharacterized by distinctive desmoplasia stemming from cancer-associated fibroblast, matrix \\nmetalloproteinases, and hyaluronan, may promote the immunosuppressive characteristic of \\nthe TME. These multifaceted compartments are viewed as responsible, in part, for the \\nresistance to most single-agent therapeutic approaches.42–45 Many clinical trials that are \\nunderway are designed to increase the sensitivity of PDAC to the immune system with \\nthe goal of overcoming the immunosuppressive characteristic of the TME (eTable 1 in the \\nSupplement).46,47\\nClinical Manifestations and Presentation of Pancreatic Cancer\\nThe presenting symptoms of PDAC are often vague and nonspecific. Most patients \\npresent with either locally advanced (unresectable) or metastatic disease. In a prospective'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 4}, page_content='cohort study of 391 participants 40 years or older who were suspected of having PDAC, \\ninitial symptoms were compared among 119 participants who were ultimately diagnosed \\nwith PDAC, 47 with other cancers, and 225 without PDAC. In this study, no initial \\nsymptoms differentiated participants diagnosed with PDAC from those who ultimately \\ndid not have PDAC, including the 3 most common symptoms: decreased appetite (28% \\nvs 31%), indigestion (27% vs 39%), and change in bowel habit (27% vs 22%).48 Most \\ntumors (approximately 70%) arise at the head of the pancreas and often present with \\nbiliary obstruction leading to dark urine (49%), jaundice (49%), appetite loss (48%), \\nfatigue (approximately 51%), weight loss (approximately 55%), and exocrine pancreatic \\ninsufficiency (25%). In contrast, individuals with body and tail pancreatic cancers present \\nwith more nonspecific symptoms, including abdominal pain, back pain, and cachexia-related'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 4}, page_content='symptoms (appetite loss, weight loss, fatigue). New-onset or worsening of preexisting \\ndiabetes may be a sign of PDAC and warrants evaluation.49 Rarely, acute pancreatitis can be \\na primary manifestation of PDAC and occurs in about 3% of patients with newly diagnosed \\nPDAC. Referral to an experienced multidisciplinary team is recommended.Park et al. Page 5\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 5}, page_content='Diagnosis and Evaluation of Pancreatic Cancer\\nPancreas computed tomography (CT) angiography with chest and pelvis CT can be used \\nin the assessment of vascular anatomy and stage of disease and are recommended at \\ndiagnosis. The degree of contact between the tumor and local blood vessels (ie, the superior \\nmesenteric and portal veins as well as the celiac, hepatic, and superior mesenteric arteries) \\nis categorized as either uninvolved, abutted, or encased. Abutment implies that the tumor \\nhas 180° or less of blood vessel involvement and encasement implies greater than 180° \\nof circumferential tumor-vessel involvement (Figure 1). This information is important to \\ndefine the most optimal initial treatment. Common sites of PDAC metastases are liver \\n(90%), lymph nodes (25%), lung (25%), peritoneum (20%), and bones (10%–15%).3 \\nMagnetic resonance imaging and cholangiopancreatography can help determine whether'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 5}, page_content='indeterminate liver lesions are likely to represent metastases and identify cancers that \\nmay be poorly characterized on CT imaging. Positron emission tomography/CT using a \\nfluorodeoxyglucose tracer is a functional imaging tool that evaluates glucose metabolism in \\nthe tumor and can help distinguish benign from malignant lesions in the pancreas; however, \\nit lacks the spatial resolution and can detect glucose uptake from infection, inflammation \\nalso confounding interpretation.50 Positron emission tomography/CT is not considered a \\nroutine staging tool.\\nEndoscopic ultrasonography is used to visualize a pancreas mass directly, secure a definitive \\ncytologic or histologic diagnosis, define the degree of tumor-vascular involvement, evaluate \\nregional lymph nodes, and evaluate the potential for complete resection. Fine-needle \\ncore biopsy (preferred over fine-needle aspiration) of a tumor guided by endoscopic'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 5}, page_content='ultrasonography is recommended to obtain a histologic diagnosis and to provide material \\nfor molecular testing (Table 1). Visualization of an obstructed biliary tree is performed \\nby endoscopic retrograde cholangiopancreatography, with decompression most often \\nachieved by placing a metallic biliary stent. Serum carbohydrate antigen 19–9 is a well-\\nestablished biomarker for PDAC and is useful for monitoring treatment response. Although \\ncarbohydrate antigen 19–9 is not sufficiently sensitive or specific for routine screening, \\nits value as a screening tool is being revisited.51,52 Other investigational blood-based \\nbiomarkers, including cell-free DNA, exosomes, and circulating tumor cells, may also be \\nuseful for monitoring treatment response and evaluating therapy resistance.53\\nClinical Staging and Multidisciplinary Management of Localized Disease\\nResectability, defined as the ability to completely remove the cancer, is assessed to select'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 5}, page_content='treatment for localized PDAC (Table 1).54 The American Joint Committee on Cancer \\n(AJCC) tumor, node, and metastasis classification is used to assess prognosis.55 For the \\npractical treatment planning, each case is defined as resectable PDAC, borderline resectable \\nPDAC (BRPC), or locally advanced PDAC (LAPC) based on the degree of tumor contact \\nand invasion into the superior mesenteric, hepatic artery, or celiac vasculature (Figure 1). \\nLocalized disease consists of a spectrum of resectability, including resectable (operable), \\nborderline resectable, and locally advanced and inoperable disease. Characterizing localized \\ndisease is best performed by multidisciplinary review, including physicians from surgical \\noncology, radiology, medical oncology, and radiation oncology disciplines. Several Park et al. Page 6\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 6}, page_content='classifications of resectability are used.56 Tumors are typically considered resectable when \\nthere is minimal or no contact with major vessels. However, BRPC may have venous \\ninvolvement and/or partial arterial involvement. There is growing interest in evaluating \\nneoadjuvant systemic therapy with or without radiotherapy for BRPC and resectable PDAC. \\nLocally advanced PDAC is unresectable at presentation due to vessel invasion.\\nThe optimal procedure for resection of the primary tumor depends on tumor location and \\nits relationship to the bile duct and vasculature. Generally, tumors in the pancreas head \\nand uncinate process require a pancreaticoduodenectomy, or “Whipple procedure,” while \\ntumors in the pancreatic neck (without bile duct involvement), body, and tail require a \\ndistal pancreatectomy. Vessel invasion may require vascular resection and reconstruction. \\nPancreaticoduodenectomy is associated with high rates of adverse events, including delayed'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 6}, page_content='gastric emptying (10%) and pancreatic leak (13%).57 The best outcomes are attained by \\nsurgeons who perform more than 20 pancreaticoduodenectomy procedures per year and \\nconduct surgery in a high-volume center. Minimally invasive pancreatectomy has been \\ndemonstrated to be safe, with similar complication rates as open pancreatectomy (OR, 0.67 \\n[95% CI, 0.39–1.16]) as well as shorter hospital stay (weighted mean difference, 3.7 days) \\ncompared with open pancreatectomy.58,59 Pancreatectomy should be performed when a \\nmargin-negative resection is feasible. En bloc resection and reconstruction of the portal vein \\nin patients with tumor invasion into this blood vessel is used to obtain a margin-negative \\nresection. This undertaking results in a similar prognosis than in patients whose tumors do \\nnot invade the portal vein and is standard therapy for patients with BRPC.60\\nCurrent multidisciplinary management paradigms include early integration of supportive'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 6}, page_content='care, prehabilitation strategies with physical therapy, occupational therapy (prior to \\nproceeding to the operating room), nutritional management (including pancreas enzyme \\nsupplementation), advance care planning, and increasing use of patient-reported outcome \\nmeasures to enhance quality of life (eTable2 in the Supplement).61\\nAdvances in Adjuvant Therapy for Resected Pancreatic Cancer\\nThe recommended adjuvant chemotherapy after resection of PDAC is either modified \\nFOLFIRINOX (fluorouracil, oxaliplatin, irinotecan, leucovorin) for individuals with high \\nfunctional status or gemcitabine and capecitabine or gemcitabine alone for individuals \\nwith poorer functional status. Recommendations for adjuvant therapy are based on several \\nimportant trials from the past 2 decades.5,62–64 The main chemotherapy agents are DNA-\\ndamaging agents, which directly affect DNA synthesis and repair (oxaliplatin, irinotecan),'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 6}, page_content='and antimetabolites, such as gemcitabine and fluorouracil (Table 2). The efficacy of adjuvant \\nchemotherapy in resected PDAC was defined in the CONKO-001 trial, in which 368 \\npatients who underwent surgical resection of PDAC were randomized to receive 6 months \\nof adjuvant gemcitabine or undergo observation (eTable 3 in the Supplement). Superior \\nmedian overall survival was observed in patients treated with gemcitabine compared \\nwith those who underwent observation (22.8 vs 20.2 months; hazardratio [HR], 0.76 \\n[95% CI, 0.61–0.95]), representing a modest prolongation of survival.62 Subsequent trials \\ncompared gemcitabine with single-agent fluorouracil as well as 2- and 3-drug combination \\nregimens.5,63,64 The ESPAC-4 phase 3 trial demonstrated an added survival benefit of Park et al. Page 7\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 7}, page_content='dual-agent therapy over gemcitabine alone. In this trial, 730 patients were randomized \\nto receive 6 months of adjuvant gemcitabine plus capecitabine, an oral antimetabolite, \\nor gemcitabine alone. Combination therapy improved median overall survival compared \\nwith gemcitabine alone (28.0 vs 25.5 months; HR, 0.82 [95% CI, 0.68–0.98]).64 Most \\nrecently, in the 2018 multicenter PRODIGE-24 trial, 493 patients with resected PDAC, along \\nwith a low serum carbohydrate antigen 19–9 (< 180 U/mL) and an excellent performance \\nstatus (Eastern Cooperative Oncology Group score, 0–1), were randomized to receive 6 \\nmonths of adjuvant modified FOLFIRINOX or gemcitabine alone. In this trial, favorable \\nsurvival occurred in both groups relative to prior trials with gemcitabine in the adjuvant \\nsetting and likely reflected inclusion of more highly selected patients: patients treated with \\nmodified FOLFIRINOX had an overall survival of 54.4 months, compared with 35 months'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 7}, page_content='in patients treated with gemcitabine (HR, 0.64 [95% CI, 0.48–0.86]).5 Thus, modified \\nFOLFIRINOX is recommended as standard adjuvant therapy in individuals with excellent \\nfunctional status after surgical resection of PDAC. Overall, patients for whom treatment with \\nmodified FOLFIRINOX is not suitable can be considered for gemcitabine/capecitabine or \\ngemcitabine alone.63,64 The role of radiotherapy as an adjuvant therapy for resected PDAC \\nis controversial. Older studies did not support adjuvant radiation for PDAC because no \\noverall survival advantage has been demonstrated.68,69\\nNeoadjuvant and Perioperative Therapy for Resectable and Borderline \\nResectable Pancreatic Cancer\\nNeoadjuvant therapy, or preoperative therapy, can eradicate occult metastatic disease and \\nincrease the number of patients eligible for systemic therapy. The latter is important because \\na significant percentage of patients are unable to receive adjuvant therapy because of'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 7}, page_content='operative morbidity. Recent nonrandomized prospective trials demonstrated high completion \\nrates, of 83% to 90%, in patients receiving neoadjuvant FOLFIRINOX.7,70 In a phase 2 \\ntrial, 39 of 43 patients with BRPC received 4 months of FOLFIRINOX.7,70 Similarly, \\nin the Southwest Oncology Group S1505 trial, 46 of 55 patients completed neoadjuvant \\nFOLFIRINOX therapy.7 Another advantage is potential downstaging prior to undergoing \\nsurgery, facilitating a margin-negative resection.70,71 This was demonstrated in a multi-\\ninstitutional trial that reported improved margin-negative resection rates in patients receiving \\nneoadjuvant therapy compared with initial surgery in 58 patients with BRPC (82.4% vs \\n33.3%; P = .01).72\\nThe role of radiotherapy in localized PDAC remains unclear and is being evaluated in \\nongoing investigations.73–76 Neoadjuvant chemoradiotherapy has demonstrated potential \\nbenefit in the phase 3 PREOPANC trial, in which 236 patients were randomized to receive'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 7}, page_content='neoadjuvant gemcitabine-based chemoradiation followed by surgery or initial surgery, \\nboth followed by adjuvant gemcitabine. An overall survival benefit was observed in the \\npredefined subgroup of 113 patients with BRPC who were treated with neoadjuvant \\nchemoradiotherapy (17.6 vs 13.2 months; HR, 0.62 [95% CI, 0.40–0.95]).74 The \\nALLIANCE A021501 trial, a randomized phase 2 trial, evaluated perioperative modified \\nFOLFIRINOX with or without neoadjuvant stereotactic body radiotherapy in 126 patients \\nwith BRPC. The addition of stereotactic body radiotherapy to neoadjuvant modified Park et al. Page 8\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 8}, page_content='FOLFIRNOX did not improve median overall survival (31.0 months [95% CI, 22.2 to not \\nreached] for the modified FOLFIRINOX group and 17.1 months [95% CI, 12.8– 24.4] for \\nthe modified FOLFIRINOX plus stereotactic body radiotherapy group). Data for both groups \\nwere compared with historical data and the study did not have sufficient statistical power to \\ncompare the groups directly.77 Current guidelines support neoadjuvant chemotherapy with \\nor without radiotherapy as an option in both BRPC and LAPC.54 Eligibility for surgical \\nresection in BRPC and LAPC requires assessment by a multidisciplinary team.\\nThe benefit of neoadjuvant therapy in resectable PDAC is undergoing evaluation. Potential \\nlimitations of neoadjuvant therapy include the lack of a major tumor response to neoadjuvant \\ntherapy in most patients.7Inadequate tumor response may facilitate tumor progression, \\nobviating the opportunity to completely resect the tumor. However, the importance of this'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 8}, page_content='phenomenon remains unclear. Neoadjuvant therapy adds complexity to multidisciplinary \\ntreatment planning. It requires a pretreatment biopsy and endoscopic stent placement in \\npatients with biliary obstruction. In patients with resectable disease, preoperative biliary \\ndrainage was associated with perioperative complications, such as pancreatitis in 7% of \\npatients, cholangitis in 26%, stent occlusion in 15%, and postoperative wound infection \\nin 13%.78 A randomized phase 2 Southwest Oncology Group (SWOG) S1505 trial of \\n102 patients evaluated perioperative modified FOLFIRINOX or gemcitabine and albumin-\\nbound paclitaxel. Results showed no difference in overall survival between the modified \\nFOLFIRINOX and gemcitabine plus albumin-bound paclitaxel, with 2-year overall survival \\nrates of 47% (95% CI, 31%–61%) and 48% (95% CI, 31%–63%).7 Uncertainties related to \\nthe efficacy of neoadjuvant therapy in patients with resectable PDAC may be addressed by'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 8}, page_content='an ongoing phase 3 trial (A021806) comparing perioperative modified FOLFIRINOX with \\nadjuvant modified FOLFIRINOX in patients with resectable PDAC.\\nTherapy of LAPC\\nLAPC is an inoperable disease at diagnosis, and approximately 80% of patients are \\nunlikely to have sufficient tumor response from neoadjuvant therapy to become eligible \\nfor surgical resection. To achieve disease control, initial treatment typically consists of \\nchemotherapy regimens, such as modified FOLFIRINOX or albumin-bound paclitaxel and \\ngemcitabine.79 The role of radiation in LAPC is controversial. A pooled analysis of 11 \\ntrials involving 794 patients reported that chemoradiation was associated with improved \\nsurvival, compared with radiotherapy alone (2 trials [168 patients]; HR, 0.69 [95% CI, 0.51–\\n0.94]), but chemoradiation followed by chemotherapy did not improve survival more than \\nchemotherapy (2 trials [134 patients]; HR, 0.79 [95% CI, 0.32–1.95]).80 The SCALOP trial'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 8}, page_content='evaluated the use of capecitabine or gemcitabine combined with radiation. The capecitabine \\ngroup had superior median overall survival compared with the gemcitabine group (15.2 vs \\n13.4 months; adjusted HR, 0.39 [95% CI, 0.18–0.81]; P = .012).81 The role of radiation, \\nthe optimum radiation modality, and the dosing schedule for radiation in LAPC all remain \\nunclear. Innovative radiation strategies, including high-dose “ablative” radiotherapy, are \\nunder investigation.Park et al. Page 9\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 9}, page_content='Standard Therapies for Metastatic Pancreatic Cancer\\nMultiagent cytotoxic regimens have improved survival in advanced PDAC.3–5,67 Current \\nstandard first-line regimens for patients with metastatic disease include gemcitabine \\nand albumin-bound paclitaxel or modified FOLFIRINOX (Table 2; eTable 3 in the \\nSupplement).3,4 The Metastatic Pancreatic Cancer Trial (MPACT) trial of 861 patients \\nwith untreated metastatic PDAC reported an overall survival benefit for gemcitabine and \\nalbumin-bound paclitaxel compared with gemcitabine (median survival, 8.5 vs 6.7 months; \\nHR, 0.72 [95% CI, 0.62–0.83]; P < .001).4 The PRODIGE trial of 342 patients with \\nuntreated metastatic PDAC reported that mean survival was better with FOLFIRINOX \\ntreatment compared with gemcitabine (11.1 vs 6.8 months; HR, 0.57 [95% CI, 0.45–0.73]; \\nP < .001).3 For 417 patients with metastatic PDAC and disease progression receiving \\ngemcitabine therapy, the NAPOLI-1 trial demonstrated superiority of overall survival for'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 9}, page_content='the combination of nanoliposomal irinotecan, fluorouracil, and leucovorin, with a median \\n6.1 months, compared with fluorouracil and leucovorin, with a median of 4.2 months (HR, \\n0.67 [95% CI, 0.49–0.92]; P = .012).67These trials were conducted in patients without \\nselection for any specific disease or genetic characteristic. In contrast, the POLO (Pancreas \\nOlaparib Ongoing) trial validated a genetic biomarker, germline BRCA1/2  variation, leading \\nto US Food and Drug Administration approval of olaparib, apoly (ADP-ribose) polymerase \\ninhibitor. Olaparib or placebo was administered as a maintenance treatment in patients \\nwith a germline BRCA1/2  variation and metastatic PDAC following initial platinum-based \\nchemotherapy and was approved based on a progression-free survival benefit compared with \\nplacebo (7.4 vs 3.8 months; HR, 0.53 [95% CI, 0.35–0.82]; P = .004).8 Of note, there was \\nno difference in overall survival between the placebo and olaparib groups in the POLO trial'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 9}, page_content='(HR, 0.83 [95% CI, 0.56–1.22]; P = .35).\\nSymptom Management and Supportive Care Approaches in Pancreatic \\nCancer\\nSupportive care by a multidisciplinary team should be integrated with therapeutic \\nmanagement of PDAC to maximize length of life, quality of life, and symptom \\ncontrol. Specifically, attention to nutrition, pain management, management of thromboses, \\npsychosocial needs, and advance care planning are among the most important \\nconsiderations.61 Other challenges of PDAC include bile duct and duodenal obstruction. \\nBiliary obstruction is managed with endobiliary metallic stent placement or surgical biliary-\\nenteric bypass.82 Gastric outlet or duodenal obstruction is managed via endoscopic stent \\nplacement, which has been shown to have noninferior efficacy and greater durability relative \\nto gastrojejunostomy.83\\nNovel Therapies for Pancreatic Cancer\\nA subgroup of 10% to 15% of individuals with PDAC have DNA damage repair gene'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 9}, page_content='alterations other than BRCA . Novel combination strategies evaluating targeted agents and \\nimmune therapy combinations are undergoing testing for patients with PDAC associated \\nwith impaired DNA damage repair.9,84 Single-agent PD-1 blockade has US Food and Drug \\nAdministration approval for mismatch repair deficiency in any tumor. Mismatch repair Park et al. Page 10\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 10}, page_content='deficiency occurs in approximately 1% of individuals with PDAC and is defined by either \\ngermline or somatic alterations or loss in mismatch repair deficiency genes, such as MLH1 \\nand MSH2 .29,85 KRAS  missense variants in codon G12C in PDAC occur in 1% to 2% of \\npatients with PDAC, and early-phase assessment of the KRAS  G12Callele-specific inhibitor \\nsotorasib demonstrated 1 instance of partial response (>30% tumor reduction) and stable \\ndisease in a cohort of 12 patients with PDAC who have this variation. The KRAS  wild-type \\nsubset of PDAC (absence of KRAS  variation) is observed in 6% to 8% of all patients \\nwith PDAC and in up to 16% to 18% in patients younger than 50 years at diagnosis.86 \\nIn this setting, alternative oncogenic drivers are present and entrectinib and larotrectinib \\nhave activity in TRK  fusion (<1%) and zenocutuzumab (MCLA-128) has activity in NRG-1 \\nfusion (<1%) PDAC.87,88\\nThere are multiple drugs targeting the epithelial component, signaling pathways,'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 10}, page_content='metabolism, and the TME of PDAC (Figure 2). Single or combination immune \\ncheckpoint blockade inhibitors, such as durvalumab and tremelimumab, are ineffective for \\nPDAC.44,45,89 However, an early efficacy signal of an objective response rate of 67% (8 of \\n12 participants in all cohorts and median overall survival of 20.1 months [95% CI, 10.5 to \\nnot estimable] among 24 dose-limiting toxicity-evaluable participants) has been observed for \\nthe combination of the CD40 agonistic antibody sotigalimab with the checkpoint inhibitor \\nnivolumab and chemotherapy.90 Adenosine is an immunosuppressive metabolite in the \\nTME. Depleting adenosine, using both small molecule–targeting agents (eg, AB680) or with \\nantibody therapy (eg, oleclumab), represent novel metabolism-directed approaches being \\ninvestigated in PDAC.91 eTable 1 in the Supplement summarizes select ongoing trials in \\nPDAC.\\nLimitations\\nThis review has several limitations. First, it is not a systematic review and the quality of'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 10}, page_content='included literature was not formally evaluated. Second, some relevant studies may have been \\nmissed. Third, it does not cover all aspects of the epidemiology, diagnosis, and management \\nof pancreatic cancer.\\nConclusions\\nApproximately 60 000 new cases of PDAC are diagnosed per year, and about 50% of \\npatients have advanced disease at diagnosis. The incidence of PDAC is increasing. Currently \\navailable cytotoxic therapies for advanced disease are modestly effective. For all patients, \\nmultidisciplinary management, comprehensive germline testing, and integrated supportive \\ncare is recommended.\\nSupplementary Material\\nRefer to Web version on PubMed Central for supplementary material.Park et al. Page 11\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='Funding/Support:\\nCancer Center Support Grant P30 CA008748; David M. Rubenstein Center for Pancreas Cancer Research; Paul \\nCalabresi Career Development Award K12 CA184746; Parker Institute for Immunotherapy Pilot Grant; Elsa U. \\nPardee Foundation Grant.\\nConflict of Interest Disclosures:\\nDr Park reported receiving grant and research support from Astellas, Gossamer Bio, and Merck and providing \\nconsultancy to Ipsen. Dr O’Reilly reported receiving grants and research funding to the institution from Genentech-\\nRoche, Celgene-BMS, BioNTech, Arcus, AstraZeneca, and BioAtla; personal fees for serving on a data and \\nsafety monitoring board from Cytomx Therapeutics, Rafael Therapeutics, personal fees from Sobi Consulting, \\nnon-financial support from Silenseed Consulting, personal fees from Molecular Templates Consulting, personal \\nfees from Boehringer Ingelheim Consulting, personal fees from BioNTech Consulting, personal fees from Ipsen'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='Consulting, personal fees from Polaris Consulting, and personal fees from Merck Consulting during the conduct of \\nthe study; other from Bayer Spouse consulting, other from Celgene/BMS Spouse consulting, other from Genentech-\\nRoche Spouse consulting, and other from Eisai Spouse consulting outside the submitted work. No other disclosures \\nwere reported.\\nRole of the Funder/Sponsor:\\nThe funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation \\nof the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for \\npublication.\\nREFERENCES\\n1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–\\n33. doi:10.3322/caac.21654 [PubMed: 33433946] \\n2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting \\ncancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155 \\n[PubMed: 24840647] \\n3. Conroy T, Desseigne F, Ychou M, et al. ; Groupe Tumeurs Digestives of Unicancer; PRODIGE \\nIntergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. \\n2011; 364(19):1817–1825. doi:10.1056/NEJMoa1011923 [PubMed: 21561347] \\n4. V on Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel \\nplus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369 \\n[PubMed: 24131140] \\n5. Conroy T, Hammel P, Hebbar M, et al. ; Canadian Cancer Trials Group and the Unicancer-GI–\\nPRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl \\nJ Med. 2018; 379(25):2395–2406. doi:10.1056/NEJMoa1809775 [PubMed: 30575490] \\n6. Pancreatic Adenocarcinoma, Version 1.2020. National Comprehensive Cancer Network; 2019.'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='7. Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable \\npancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–427. \\ndoi:10.1001/jamaoncol.2020.7328 [PubMed: 33475684] \\n8. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA -mutated metastatic \\npancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMoa1903387 [PubMed: \\n31157963] \\n9. O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase ii trial of gemcitabine and \\ncisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/\\nPALB2  mutation. J Clin Oncol. 2020; 38(13):1378–1388. doi:10.1200/JCO.19.02931 [PubMed: \\n31976786] \\n10. Wong MCS, Jiang JY , Liang M, Fang Y , Yeung MS, Sung JJY . Global temporal patterns of \\npancreatic cancer and association with socioeconomic development. Sci Rep. 2017;7(1):3165. \\ndoi:10.1038/s41598-017-02997-2 [PubMed: 28600530]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='11. Rawla P, Sunkara T, Gaduputi V . Epidemiology of pancreatic cancer: global trends, etiology and'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 11}, page_content='doi:10.1038/s41598-017-02997-2 [PubMed: 28600530] \\n11. Rawla P, Sunkara T, Gaduputi V . Epidemiology of pancreatic cancer: global trends, etiology and \\nrisk factors. World J Oncol. 2019;10(1):10–27. doi:10.14740/wjon1166 [PubMed: 30834048] Park et al. Page 12\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='12. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS. K-ras mutation in focal proliferative \\nlesions of human pancreas. Cancer Epidemiol Biomarkers Prev. 1998;7(6):515–521. [PubMed: \\n9641496] \\n13. Konstantinidis IT, Vinuela EF, Tang LH, et al. Incidentally discovered pancreatic intraepithelial \\nneoplasia: what is its clinical significance? Ann Surg Oncol. 2013;20(11):3643–3647. doi:10.1245/\\ns10434-013-3042-2 [PubMed: 23748606] \\n14. Oyama H, Tada M, Takagi K, et al. Long-term risk of malignancy in branch-\\nduct intraductal papillary mucinous neoplasms. Gastroenterology. 2020;158(1):226–237.e5. \\ndoi:10.1053/j.gastro.2019.08.032 [PubMed: 31473224] \\n15. Tanaka M, Chari S, Adsay V , et al. ; International Association of Pancreatology. International \\nconsensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous \\ncystic neoplasms of the pancreas. Pancreatology. 2006;6(1–2):17–32. doi:10.1159/000090023 \\n[PubMed: 16327281]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='[PubMed: 16327281] \\n16. Hackert T, Fritz S, Klauss M, et al. Main-duct intraductal papillary mucinous neoplasm: \\nhigh cancer risk in duct diameter of 5 to 9mm. Ann Surg. 2015;262(5):875–880. doi:10.1097/\\nSLA.0000000000001462 [PubMed: 26583679] \\n17. Vege SS, Ziring B, Jain R, et al. American Gastroenterological Association Institute guideline \\non the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. \\n2015;148(4):819–822. doi:10.1053/j.gastro.2015.01.015 [PubMed: 25805375] \\n18. Owens DK, Davidson KW, Krist AH, et al. ; US Preventive Services Task Force. Screening for \\npancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. \\nJAMA. 2019;322(5):438–444. doi:10.1001/jama.2019.10232 [PubMed: 31386141] \\n19. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an \\nanalysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol.'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='2012; 23(7):1880–1888. doi:10.1093/annonc/mdr541 [PubMed: 22104574] \\n20. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic \\ncancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535–545. doi:10.1007/\\ns00423-007-0266-2 [PubMed: 18193270] \\n21. Wang YT, Gou YW, Jin WW, Xiao M, Fang HY . Association between alcohol intake and the risk \\nof pancreatic cancer: a dose-response meta-analysis of cohort studies. BMC Cancer. 2016;16:212. \\ndoi:10.1186/s12885-016-2241-1 [PubMed: 26968702] \\n22. Genkinger JM, Spiegelman D, Anderson KE, et al. Alcohol intake and pancreatic cancer risk: \\na pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009;18(3):765–\\n776. doi:10.1158/1055-9965.EPI-08-0880 [PubMed: 19258474] \\n23. Johansen D, Stocks T, Jonsson H, et al. Metabolic factors and the risk of pancreatic \\ncancer: a prospective analysis of almost 580,000 men and women in the Metabolic'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2307–2317. \\ndoi:10.1158/1055-9965.EPI-10-0234 [PubMed: 20826833] \\n24. Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the \\nUSA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4(3):e137–e147. \\ndoi:10.1016/S2468-2667(18)30267-6 [PubMed: 30733056] \\n25. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently \\nsporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382–3390. doi:10.1200/\\nJCO.2017.72.3502 [PubMed: 28767289] \\n26. Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer \\npredisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401–2409. doi:10.1001/\\njama.2018.6228 [PubMed: 29922827] \\n27. Golan T, Kindler HL, Park JO, et al. Geographic and ethnic heterogeneity of germline BRCA1  or'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='BRCA2  mutation prevalence among patients with metastatic pancreatic cancer screened for entry \\ninto the POLO trial. J Clin Oncol. 2020;38(13):1442–1454. doi:10.1200/JCO.19.01890 [PubMed:'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='BRCA2  mutation prevalence among patients with metastatic pancreatic cancer screened for entry \\ninto the POLO trial. J Clin Oncol. 2020;38(13):1442–1454. doi:10.1200/JCO.19.01890 [PubMed: \\n32073954] \\n28. Hu C, LaDuca H, Shimelis H, et al. Multigene hereditary cancer panels reveal high-risk pancreatic \\ncancer susceptibility genes. JCO Precis Oncol. 2018;2. doi:10.1200/po.17.00291Park et al. Page 13\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='29. Hu ZI, Hellmann MD, Wolchok JD, et al. Acquired resistance to immunotherapy in MMR-D \\npancreatic cancer. Journal Immunother Cancer. 2018;6(1):127. doi:10.1186/s40425-018-0448-1\\n30. Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O’Reilly EM. An emerging paradigm for \\ngermline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical \\npractice: a review. JAMA Oncol. 2020;6(5):764–771. doi:10.1001/jamaoncol.2019.5963 [PubMed: \\n32053139] \\n31. Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage \\npancreatic intraepithelial neoplasia. Gastroenterology. 2012; 142(4):730–733.e9. doi:10.1053/\\nj.gastro.2011.12.042 [PubMed: 22226782] \\n32. Waddell N, Pajic M, Patch AM, et al. ; Australian Pancreatic Cancer Genome Initiative. Whole \\ngenomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–\\n501. doi:10.1038/nature14169 [PubMed: 25719666]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='33. Aguirre AJ, Nowak JA, Camarda ND, et al. Real-time genomic characterization of \\nadvanced pancreatic cancer to enable precision medicine. Cancer Discov. 2018;8(9):1096–1111. \\ndoi:10.1158/2159-8290.CD-18-0275 [PubMed: 29903880] \\n34. Bailey P, Chang DK, Nones K, et al. ; Australian Pancreatic Cancer Genome Initiative. \\nGenomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–\\n52. doi:10.1038/nature16965 [PubMed: 26909576] \\n35. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and \\nstroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–\\n1178. doi:10.1038/ng.3398 [PubMed: 26343385] \\n36. Hayashi A, Fan J, Chen R, et al. A unifying paradigm for transcriptional heterogeneity \\nand squamous features in pancreatic ductal adenocarcinoma. Nature Cancer. 2020;1(1):59–74. \\ndoi:10.1038/s43018-019-0010-1 [PubMed: 35118421]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='37. Aung KL, Fischer SE, Denroche RE, et al. Genomics-driven precision medicine for advanced \\npancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–\\n1354. doi:10.1158/1078-0432.CCR-17-2994 [PubMed: 29288237] \\n38. Knox JJClinical advances in pancreas adenocarcinoma. Cancer Res. 2020;80(22 suppl). AACR \\nVirtual Special Conference on Pancreatic Cancer abstract IA-08.\\n39. Lowery MA, Jordan EJ, Basturk O, et al. Real-time genomic profiling of pancreatic ductal \\nadenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res. \\n2017;23(20):6094–6100 [PubMed: 28754816] \\n40. Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic \\ncancer receiving matched therapies following molecular profiling: a retrospective analysis \\nof the Know Your Tumor registry trial. Lancet Oncol. 2020;21(4):508–518. doi:10.1016/\\nS1470-2045(20)30074-7 [PubMed: 32135080]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='41. Balachandran VP, Łuksza M, Zhao JN, et al. ; Australian Pancreatic Cancer Genome Initiative; \\nGarvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; \\nUniversity of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; \\nUniversity of Melbourne, Centre for Cancer Research; University of Queensland, Institute for \\nMolecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, \\nChris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; \\nRoyal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria \\nHospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied \\nResearch on Cancer. Identification of unique neoantigen qualities in long-term survivors \\nof pancreatic cancer. Nature. 2017;551(7681):512–516. doi:10.1038/nature24462 [PubMed: \\n29132146]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='29132146] \\n42. Beatty GL, Eghbali S, Kim R. Deploying immunotherapy in pancreatic cancer: defining \\nmechanisms of response and resistance. Am Soc Clin Oncol Educ Book. 2017;37:267–278. \\ndoi:10.1200/EDBK_175232 [PubMed: 28561678]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 13}, page_content='mechanisms of response and resistance. Am Soc Clin Oncol Educ Book. 2017;37:267–278. \\ndoi:10.1200/EDBK_175232 [PubMed: 28561678] \\n43. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and \\nPD-L1. Cancer Res. 2015;75(11):2139–2145. doi:10.1158/0008-5472.CAN-15-0255 [PubMed: \\n25977340] \\n44. Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed \\ndeath ligand 1 expression, and tumor mutational burden predict efficacy in patients treated Park et al. Page 14\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327. \\ndoi:10.1200/JCO.2018.78.2276 [PubMed: 30557521] \\n45. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for \\nlocally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–833. \\ndoi:10.1097/CJI.0b013e3181eec14c [PubMed: 20842054] \\n46. Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer: \\nclinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527–540. doi:10.1038/\\ns41571-020-0363-5 [PubMed: 32398706] \\n47. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel \\ntherapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17(2):108–123. \\ndoi:10.1038/s41571-019-0281-6 [PubMed: 31705130] \\n48. Walter FM, Mills K, Mendonça SC, et al. Symptoms and patient factors associated with'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort \\nstudy. Lancet Gastroenterol Hepatol. 2016;1(4):298–306. doi:10.1016/S2468-1253(16)30079-6 \\n[PubMed: 28404200] \\n49. Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on pancreas cancer screening \\nin high-risk individuals: expert review. Gastroenterology. 2020;159(1):358–362. doi:10.1053/\\nj.gastro.2020.03.088 [PubMed: 32416142] \\n50. Wang XY , Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment \\nof resectability and metabolic response of pancreatic cancer. World J Gastroenterol. \\n2014;20(42):15580–15589. doi:10.3748/wjg.v20.i42.15580 [PubMed: 25400441] \\n51. Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19–9 represents a \\nmarker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. \\nHPB (Oxford). 2014;16(5):430–438. doi:10.1111/hpb.12154 [PubMed: 23991810]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='52. Fahrmann JF, Schmidt CM, Mao X, et al. Lead-time trajectory of CA19–9 as an anchor marker \\nfor pancreatic cancer early detection. Gastroenterology. 2021;160(4):1373–1383. doi:10.1053/\\nj.gastro.2020.11.052 [PubMed: 33333055] \\n53. Lee J-S, Park SS, Lee YK, Norton JA, Jeffrey SS. Liquid biopsy in pancreatic ductal \\nadenocarcinoma: current status of circulating tumor cells and circulating tumor DNA. Mol Oncol. \\n2019;13(8):1623–1650. doi:10.1002/1878-0261.12537 [PubMed: 31243883] \\n54. Vauthey JN, Dixon E. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline \\nResectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol. \\n2009;16(7):1725–1726. doi:10.1245/s10434-009-0409-5 [PubMed: 19396495] \\n55. Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional validation study of the \\nAmerican Joint Commission on Cancer (8th Edition) changes for T and N staging \\nin patients with pancreatic adenocarcinoma. Ann Surg. 2017;265(1):185–191. doi:10.1097/'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='SLA.0000000000001763 [PubMed: 27163957] \\n56. Gilbert JW, Wolpin B, Clancy T, et al. Borderline resectable pancreatic cancer: conceptual \\nevolution and current approach to image-based classification. Ann Oncol. 2017;28(9):2067–2076. \\ndoi:10.1093/annonc/mdx180 [PubMed: 28407088] \\n57. Schmidt CM, Turrini O, Parikh P, et al. Effect of hospital volume, surgeon experience, and surgeon \\nvolume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch \\nSurg. 2010;145(7):634–640. doi:10.1001/archsurg.2010.118 [PubMed: 20644125] \\n58. Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, et al. Minimally-invasive vs open \\npancreaticoduodenectomy: systematic review and meta-analysis. J Am Coll Surg. \\n2014;218(1):129–139. doi:10.1016/j.jamcollsurg.2013.09.005 [PubMed: 24275074] \\n59. de Rooij T, Lu MZ, Steen MW, et al. ; Dutch Pancreatic Cancer Group. Minimally invasive versus \\nopen pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='registry studies. Ann Surg. 2016;264(2):257–267. doi:10.1097/SLA.0000000000001660 [PubMed: \\n26863398]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 14}, page_content='open pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and \\nregistry studies. Ann Surg. 2016;264(2):257–267. doi:10.1097/SLA.0000000000001660 [PubMed: \\n26863398] \\n60. Ramacciato G, Nigri G, Petrucciani N, et al. Pancreatectomy with mesenteric and portal vein \\nresection for borderline resectable pancreatic cancer: multicenter study of 406 patients. Ann Surg \\nOncol. 2016;23(6):2028–2037. doi:10.1245/s10434-016-5123-5 [PubMed: 26893222] Park et al. Page 15\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='61. Moffat GT, Epstein AS, O’Reilly EM. Pancreatic cancer: a disease in need: optimizing and \\nintegrating supportive care. Cancer. 2019;125(22): 3927–3935. doi:10.1002/cncr.32423 [PubMed: \\n31381149] \\n62. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term \\noutcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. \\nJAMA. 2013;310(14):1473–1481. doi:10.1001/jama.2013.279201 [PubMed: 24104372] \\n63. Neoptolemos JP, Stocken DD, Bassi C, et al. ; European Study Group for Pancreatic Cancer. \\nAdjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic \\ncancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–1081. doi:10.1001/\\njama.2010.1275 [PubMed: 20823433] \\n64. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and \\ncapecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='(ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–\\n1024. doi:10.1016/s0140-6736(16)32409-6 [PubMed: 28129987] \\n65. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in \\npatients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. \\nJAMA. 2007;297(3):267–277. doi:10.1001/jama.297.3.267 [PubMed: 17227978] \\n66. Neoptolemos JP, Palmer DH, Ghaneh P, et al. ; European Study Group for Pancreatic Cancer. \\nComparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients \\nwith resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. \\nLancet. 2017;389(10073):1011–1024. doi:10.1016/S0140-6736(16)32409-6 [PubMed: 28129987] \\n67. Wang-Gillam A, Li CP, Bodoky G, et al. ; NAPOLI-1 Study Group. Nanoliposomal \\nirinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. \\n2016;387(10018):545–557. doi:10.1016/S0140-6736(15)00986-1 [PubMed: 26615328] \\n68. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after \\ncurative resection of cancer of the pancreas and periampullary region: phase III trial of \\nthe EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–782. \\ndoi:10.1097/00000658-199912000-00006 [PubMed: 10615932] \\n69. Neoptolemos JP, Stocken DD, Friess H, et al. ; European Study Group for Pancreatic Cancer. A \\nrandomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N \\nEngl J Med. 2004;350(12):1200–1210. doi:10.1056/NEJMoa032295 [PubMed: 15028824] \\n70. Murphy JE, Wo JY , Ryan DP, et al. Total neoadjuvant therapy with folfirinox followed by \\nindividualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='2 clinical trial. JAMA Oncol. 2018;4(7):963–969. doi:10.1001/jamaoncol.2018.0329 [PubMed: \\n29800971] \\n71. Chawla A, Molina G, Pak LM, et al. Neoadjuvant therapy is associated with improved survival \\nin borderline-resectable pancreatic cancer. Ann Surg Oncol. 2020;27(4):1191–1200. doi:10.1245/\\ns10434-019-08087-z [PubMed: 31802297] \\n72. Jang JY , Han Y , Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with \\ngemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a \\nprospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–222. \\ndoi:10.1097/SLA.0000000000002705 [PubMed: 29462005] \\n73. Katz MHG, Ou FS, Herman JM, et al. ; Alliance for Clinical Trials on Oncology. Alliance for \\nclinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. \\nchemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='of the head of the pancreas. BMC Cancer. 2017;17(1):505. doi:10.1186/s12885-017-3441-z \\n[PubMed: 28750659]'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 15}, page_content='of the head of the pancreas. BMC Cancer. 2017;17(1):505. doi:10.1186/s12885-017-3441-z \\n[PubMed: 28750659] \\n74. Versteijne E, Suker M, Groothuis K, et al. ; Dutch Pancreatic Cancer Group. Preoperative \\nchemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic \\ncancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. \\n2020;38(16):1763–1773. doi:10.1200/JCO.19.02274 [PubMed: 32105518] \\n75. Loehrer PJ Sr, Feng Y , Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy \\nin patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. \\nJ Clin Oncol. 2011;29(31): 4105–4112. doi:10.1200/JCO.2011.34.8904 [PubMed: 21969502] Park et al. Page 16\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='76. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: \\ncomparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy \\nalone. J Natl Cancer Inst. 1988;80 (10):751–755. doi:10.1093/jnci/80.10.751 [PubMed: 2898536] \\n77. Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX \\nor mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable \\n(BR) adenocarcinoma of the pancreas. J Clin Oncol. 2021; 39(3_suppl):377. doi:10.1200/\\nJCO.2021.39.3_suppl.377\\n78. van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of \\nthe head of the pancreas. N Engl J Med. 2010;362(2):129–137. doi:10.1056/NEJMoa0903230 \\n[PubMed: 20071702] \\n79. Pancreatic Cancer, Version 1.2021. National Comprehensive Cancer Network; 2020.\\n80. Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='the management of locally advanced pancreatic cancer using radiation/combined modality therapy. \\nBr J Cancer. 2007;96(8):1183–1190. doi:10.1038/sj.bjc.6603719 [PubMed: 17406358] \\n81. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based \\nchemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, \\nphase 2 trial. Lancet Oncol. 2013;14(4):317–326. doi:10.1016/S1470-2045(13)70021-4 [PubMed: \\n23474363] \\n82. Glazer ES, Hornbrook MC, Krouse RS. A meta-analysis of randomized trials: immediate stent \\nplacement vs. surgical bypass in the palliative management of malignant biliary obstruction. J \\nPain Symptom Manage. 2014;47(2):307–314. doi:10.1016/j.jpainsymman.2013.03.013 [PubMed: \\n23830531] \\n83. Uemura S, Iwashita T, Iwata K, et al. Endoscopic duodenal stent versus surgical gastrojejunostomy \\nfor gastric outlet obstruction in patients with advanced pancreatic cancer. Pancreatology. 2018;'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='18(5):601–607. doi:10.1016/j.pan.2018.04.015 [PubMed: 29753623] \\n84. Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination \\ndeficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. \\n2020;26(13):3239–3247. doi:10.1158/1078-0432.CCR-20-0418 [PubMed: 32444418] \\n85. Florou V , Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna \\nI. Treatment rechallenge with checkpoint inhibition in patients with mismatch repair-deficient \\npancreatic cancer after planned treatment interruption. JCO Precis Oncol. 2020;4(4):780–784. \\ndoi:10.1200/PO.20.00052\\n86. Varghese AM, Singh I, Singh R, et al. Early-onset pancreas cancer: clinical descriptors, genomics, \\nand outcomes. J Natl Cancer Inst. 2021; djab038. doi:10.1093/jnci/djab038\\n87. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers \\nin adults and children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='[PubMed: 29466156] \\n88. Heining C, Horak P, Uhrig S, et al. NRG1  Fusions in KRAS  Wild-Type Pancreatic Cancer. Cancer \\nDiscov. 2018;8(9):1087–1095. doi:10.1158/2159-8290.CD-18-0036 [PubMed: 29802158] \\n89. O’Reilly EM, Oh DY , Dhani N, et al. Durvalumab with or without tremelimumab for patients with \\nmetastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. \\n2019;5(10):1431–1438. doi:10.1001/jamaoncol.2019.1588 [PubMed: 31318392] \\n90. O’Hara MH, O’Reilly EM, Varadhachary G, et al. CD40 agonistic monoclonal antibody \\nAPX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of \\nmetastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. \\n2021;22 (1):118–131. doi:10.1016/S1470-2045(20)30532-5 [PubMed: 33387490] \\n91. Bendell JC, Manji GA, Pant S, et al. A phase I study to evaluate the safety and tolerability'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='of AB680 combination therapy in participants with gastrointestinal malignancies. J Clin Oncol.'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 16}, page_content='91. Bendell JC, Manji GA, Pant S, et al. A phase I study to evaluate the safety and tolerability \\nof AB680 combination therapy in participants with gastrointestinal malignancies. J Clin Oncol. \\n2020;38 (4_suppl):TPS788. doi:10.1200/JCO.2020.38.4_suppl.TPS788Park et al. Page 17\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 17}, page_content='Box.\\nOverview of Pancreatic Cancer\\nGeneral Facts\\nApproximately 60 000 diagnoses per year in the US\\nIncidence of about 1% over lifetime\\nThe tenth to eleventh leading cause of cancer in the US\\nThird leading cause of cancer-related mortality\\n5-year survival (all-comers), 10%\\nMedian age at diagnosis, 71 years\\nMale/female incidence ratio: 1.3/1.0\\n50% of patients present with metastatic disease (AJCC stage IV)\\n30% of patients present with locally advanced disease (AJCC stage III)\\n20% of patients present with localized resectable disease (AJCC stage I and II)\\nMost common causative germline alterations: BRCA2, BRCA1, ATM, PALB2\\nCommon sites of metastasis: liver, lymph node, lung, and peritoneum\\nRare sites of metastasis: skin, brain, and leptomeninges\\nLifestyle Risk Factors\\nTobacco\\nExcess alcohol consumption (chronic pancreatitis)\\nObesity (body mass index >30), metabolic disorders, low levels of physical activity\\nDiet: high fat, polyunsaturated fats, processed meats\\nGenetic Risk Factors  a'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 17}, page_content='Hereditary breast and ovary cancer syndrome ( BRCA1/2 , PALB2 ; 5%–9%)\\nAtaxia-telangiectasia ( ATM ; approximately 3%–4%)\\nFamilial atypical multiple mole and melanoma syndrome ( CDKN2A , p16; <1%)\\nLynch syndrome ( MLH1 , MSH2 , MSH6 , PMS2 , EPCAM ; <1%)\\nHereditary pancreatitis ( PRSS1 , SPINK1 ; <1%)\\nPeutz-Jeghers syndrome ( STK11 ; <1%)\\nAbbreviation: AJCC, American Joint Committee on Cancer.\\naPercentages indicate the frequency per 100 unselected patients diagnosed with pancreas cancer.Park et al. Page 18\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 18}, page_content='Figure 1. \\nSpectrum of Localized Pancreatic CancerPark et al. Page 19\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 19}, page_content='Figure 2. \\nNovel Targets and Agents in Development in Pancreatic Cancer\\nADB indicates adenosine diphosphate; CA, carbohydrate antigen;\\nCEA, carcinoembryonic antigen; CSF, colony-stimulating factor; DDR, DNA damage repair, \\nEGFR, epidermal growth factor receptor; ILC, innate lymphoid cell; and T H1, type 1 helper \\nT cell.\\na Approved by the US Food and Drug Administration or guideline-endorsed for pancreatic \\ncancer.Park et al. Page 20\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 20}, page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptPark et al. Page 21Table 1.\\nOverview of Treatment and Prognosis by Stage of Pancreatic Cancer\\nDisease extent Localized Advanced\\nMajor vasculature involvementa Uninvolved or abutted Uninvolved or abutted Encased Distant metastasis, \\nirrespective of the major \\nvascular involvement\\nClinical stage Resectable Borderline resectable Locally advanced Metastatic\\nPrevalence of pancreatic cancer among patients \\nnewly diagnosed with PDAC, %10–15 30–35 30–35 50–55\\nAmerican Joint Committee on Cancer tumor, \\nnode, and metastasis stageI-II II-III II-III IV\\nTreatment intent Curative Curative Supportive and palliative Supportive and palliative\\nTreatment Surgery plus adjuvant \\nsystemic therapyNeoadjuvant systemic therapy; surgery \\nfor resectable patients from favorable \\nresponse; radiation for unresectable \\npatients without distant metastasisNeoadjuvant systemic therapy; surgery \\nfor resectable patients from favorable'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 20}, page_content='response; radiation for unresectable \\npatients without distant metastasisSystemic therapya\\n5-y survival rate, % 35–45 10–15 10–15 <5\\nAbbreviation: PDAC, pancreatic ductal adenocarcinoma.aThe degree of contact between the tumor and local blood vessels (ie, the superior mesenteric and portal veins as well as the celiac, hepatic, and superior mesenteric arteries) is categorized as either \\nuninvolved, abutted, or encased. Abutment implies that the tumor has 180° or less of blood vessel involvement and encasement implies greater than 180° of circumferential tumor-vessel involvement.\\nJAMA . Author manuscript; available in PMC 2022 August 09.'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 21}, page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptPark et al. Page 22Table 2.\\nSummary of Selected Clinical Trials of Systemic Therapy for Pancreatic Cancer\\nTrial Setting of therapy Study regimenComparator \\nregimenRandomized \\npatients, No.Primary end \\npointMedian \\nsurvival, moCommon serious adverse eventsa reported in \\nstudy group (% of patients)\\nCONKO-00165 \\n(2007)Adjuvant Gemcitabine Observation 368 Disease-free \\nsurvival13.4 vs 6.7 Leukopenia (2), anemia (1), thrombocytopenia \\n(1), nausea/vomiting (1), hepatic dysfunction \\n(1), diarrhea (1)\\nESPAC-466 (2017) Adjuvant Gemcitabine and \\ncapecitabineGemcitabine 730 Overall survival 28.0 vs 25.5 Neutropenia (38), leukopenia (10), hand-foot \\nsyndrome (7), fatigue (6), diarrhea (5)\\nPRODIGE-245 \\n(2018)Adjuvant mFOLFIRINOX Gemcitabine 493 Overall survival 54.4 vs 35 Neutropenia (28), diarrhea (19), paresthesia \\n(13), fatigue (11), sensory peripheral \\nneuropathy (9), nausea (6), hepatic dysfunction \\n(<5)'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 21}, page_content='(<5)\\nPRODIGE3 (2011) First-line for \\nmetastatic diseaseFOLFIRINOX Gemcitabine 342 Overall survival 11.1 vs 6.8 Neutropenia (46), fatigue (24), vomiting \\n(15), diarrhea (13), thrombocytopenia (9), \\nsensory neuropathy(9), hepatic dysfunction (7), \\nthromboembolism (7), anemia (8)\\nMPACT4 (2013) First-line for \\nmetastatic diseaseGemcitabine and \\nalbumin-bound \\npaclitaxelGemcitabine 861 Overall survival 8.5 vs 6.7 Neutropenia (38), leukopenia (31), \\nthrombocytopenia (13), anemia (13), fatigue \\n(17), peripheral neuropathy (17), diarrhea (6)\\nNAPOLI-167 (2015) For metastatic \\ndisease after \\nprogression on \\ngemcitabine therapy5-FU/LV and \\nnanoliposomal \\nirinotecan5-FU/LV 417 Overall survival 6.2 vs 4.2 Neutropenia (27), fatigue (14), diarrhea (13), \\nvomiting (11), anemia (9)\\nPOLO8 (2019) Maintenance \\nfollowing ≥4 mo \\nof platinum-based \\ntherapy (germline BRCA1/2 )Olaparib Placebo 154 Progression-free \\nsurvival7.4 vs 3.8 Anemia (11), fatigue (5), decreased appetite (3),'),\n",
       " Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 21}, page_content='abdominal pain (2), vomiting (1), arthralgia (1)\\nAbbreviations: 5-FU/LV , fluorouracil, leucovorin; mFOLFIRINOX, modified FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin).aGrade 3 or higher.\\nJAMA . Author manuscript; available in PMC 2022 August 09.')]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# `pages` contains a list of 28 Document object\n",
    "\n",
    "# Here's Page 18:\n",
    "# Document(\n",
    "#   metadata={'source': './documents/nihms-1828057.pdf', 'page': 18}, \n",
    "#   page_content='Figure 1. \\nSpectrum of Localized Pancreatic CancerPark et al. Page 19\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'\n",
    "# )\n",
    "\n",
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(f\"{len(pages)} vc {len(documents)}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import OpenAIEmbeddings\n",
    "\n",
    "embeddings = OpenAIEmbeddings()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "# pip install faiss-cpu\n",
    "from langchain_community.vectorstores import FAISS"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "vector = FAISS.from_documents(documents, embeddings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "vector.similarity_search_with_score(question)\n",
    "\n",
    "# [(Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 3}, page_content='to increasing rates of obesity and diabetes, which are potentially modifiable risk factors for \\nPDAC.\\nAbout 3.8% to 9.7% of patients with PDAC have pathogenic germline gene variants \\nthat increase susceptibility to PDAC. These variants occur mostly in DNA damage repair \\ngenes.25–27 The most common variants in PDAC include BRCA2 , BRCA1  (hereditary breast \\nand ovary cancer syndrome), and ATM  (ataxia telangiectasia syndrome). Germline BRCA2 \\nvariants are associated with an increased risk for PDAC (OR, 9.07 [95% CI, 6.33–12.98]) \\nmore commonly than BRCA1  (OR, 2.95 [95% CI, 1.49–5.60]) or ATM  variants (OR, \\n8.96 [95% CI, 6.12–12.98]).28 Uncommon (1% of patients with PDAC) but therapeutically \\nimportant inheritable germline variants also occur in PDAC in mismatch repair deficiency \\ngenes MLH1 , MSH2 , MSH6 , and PMS2  as part of Lynch syndrome.29 In 2019, the National \\nComprehensive Cancer Network guidelines recommended that all patients newly diagnosed'),\n",
    "#   0.2893287),\n",
    "#  (Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 17}, page_content='Hereditary breast and ovary cancer syndrome ( BRCA1/2 , PALB2 ; 5%–9%)\\nAtaxia-telangiectasia ( ATM ; approximately 3%–4%)\\nFamilial atypical multiple mole and melanoma syndrome ( CDKN2A , p16; <1%)\\nLynch syndrome ( MLH1 , MSH2 , MSH6 , PMS2 , EPCAM ; <1%)\\nHereditary pancreatitis ( PRSS1 , SPINK1 ; <1%)\\nPeutz-Jeghers syndrome ( STK11 ; <1%)\\nAbbreviation: AJCC, American Joint Committee on Cancer.\\naPercentages indicate the frequency per 100 unselected patients diagnosed with pancreas cancer.Park et al. Page 18\\nJAMA . Author manuscript; available in PMC 2022 August 09.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript'),\n",
    "#   0.31989175),\n",
    "#  (Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 1}, page_content='7% of patients with a BRCA  pathogenic germline variant and metastatic PDAC, olaparib, a \\npoly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that \\nimproves progression-free survival following initial platinum-based therapy.\\nCONCLUSIONS AND RELEVANCE— Approximately 60 000 new cases of PDAC are \\ndiagnosed per year, and approximately 50% of patients have advanced disease at diagnosis. The \\nincidence of PDAC is increasing. Currently available cytotoxic therapies for advanced disease \\nare modestly effective. For all patients, multidisciplinary management, comprehensive germline \\ntesting, and integrated supportive care are recommended.\\nApproximately 60 430 new diagnoses of pancreatic cancer are anticipated in the US in \\n2021.1 The incidence is rising at a rate of 0.5% to 1.0% per year, and pancreatic cancer \\nis projected to become the second-leading cause of cancer death by 2030 in the US.1,2'),\n",
    "#   0.3317449),\n",
    "#  (Document(metadata={'source': './documents/nihms-1828057.pdf', 'page': 12}, page_content='Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2307–2317. \\ndoi:10.1158/1055-9965.EPI-10-0234 [PubMed: 20826833] \\n24. Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the \\nUSA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4(3):e137–e147. \\ndoi:10.1016/S2468-2667(18)30267-6 [PubMed: 30733056] \\n25. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently \\nsporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382–3390. doi:10.1200/\\nJCO.2017.72.3502 [PubMed: 28767289] \\n26. Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer \\npredisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401–2409. doi:10.1001/\\njama.2018.6228 [PubMed: 29922827] \\n27. Golan T, Kindler HL, Park JO, et al. Geographic and ethnic heterogeneity of germline BRCA1  or'),\n",
    "#   0.34655964)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "\n",
    "prompt = ChatPromptTemplate.from_template(\n",
    "\"\"\"\n",
    "Answer the following question based on the provided context.\n",
    "\n",
    "If the context did not answer the question, do the following:\n",
    "    1. Mention that you could not find exact answer;\n",
    "    2. Provide a summary of the context.\n",
    "\n",
    "Context:\n",
    "{context}\n",
    "\n",
    "Question:\n",
    "{question}\n",
    "\n",
    "Your response:\n",
    "\n",
    "\"\"\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "llm = ChatOpenAI()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.output_parsers import StrOutputParser\n",
    "\n",
    "output_parser = StrOutputParser()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = vector.as_retriever()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_core.runnables import RunnableParallel, RunnablePassthrough\n",
    "\n",
    "setup_and_retrieval = RunnableParallel(\n",
    "    {\"context\": retriever, \"question\": RunnablePassthrough()}\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "chain = setup_and_retrieval | prompt | llm | output_parser"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = chain.invoke(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(f\"Question:\\n{question}\\n\\nAnswer:\\n{response}\")\n",
    "\n",
    "# Question:\n",
    "# What percentage of patients have pathogenic germline gene variants?\n",
    "#\n",
    "# Answer:\n",
    "# Based on the provided context, it is mentioned that about 3.8% to 9.7% of patients with PDAC have pathogenic germline gene variants. \n",
    "# \n",
    "# Therefore, the percentage of patients with pathogenic germline gene variants ranges from 3.8% to 9.7%."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "# We now can open the pdf and verify if the answer is there.\n",
    "!open ./documents/nihms-1828057.pdf"
   ]
  },
  {
   "attachments": {
    "image.png": {
     "image/png": "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"
    }
   },
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "![image.png](attachment:image.png)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
